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Antibodies targeting protein post-translational modifications (PTMs) are an essential tool in 
scientific research and clinical investigations. Due to the transient and heterogeneous nature of 
protein PTMs, high specificity and affinity of PTM-specific antibodies are critical for their 
sensitive and reproducible detection. However, recent studies have revealed an alarming degree 
of non-specific binding found in these antibodies, and whether the affinity meets the required 
detection sensitivity is unclear. To address these challenges, we investigated whether directed 
evolution could be applied to improve the affinity of a high-specific antibody targeting phospho-
threonine 231 of the human microtubule-associated protein tau. We developed a novel approach 
using yeast surface display to quantify the specificity of PTM-specific antibodies. This approach 
enabled us to measure its affinity and reveal its cross-reactivity towards the non-targets when we 
affinity-matured the single-chain variable antibody fragment through directed evolution. We 
demonstrate that directed evolution is a viable approach for obtaining high-affinity PTM-specific 
antibodies, and highlight the importance of assessing the specificity in the antibody engineering 
process.  
The yeast surface display approach allows specificity measurement when the sequence of the 
antibody is known, which makes it useful for screening antibody variants. However, for many 
antibody users, the assay is not readily applicable for measuring specificity, since the antibody 
sequence information may be unavailable. Therefore, we developed another assay that enables 
PTM-specificity measurement for existing, commercially available antibodies. The assay relies 
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on multi-color flow cytometry in human embryonic kidney (HEK) cells. We defined a specificity 
parameter termed Φ , which measures the fraction of non-specific signal in PTM-specific 
antibodies, and successfully applied the HEK cell-based assay to measure the Φ values. We 
validated the assay using antibodies with known specificity profiles, and used it to measure the 
specificity of 7 widely used phospho-tau antibodies (AT270, AT8, AT100, AT180, PHF-6, TG-3, 
and PHF-1) among others. We anticipate that the quantitative approach and parameter introduced 
here will be widely adopted as a standard for reporting the specificity for phospho-tau antibodies, 
and potentially for PTM-specific antibodies in general. 
 
 
 
 
Engineering Affinity and Specificity of Antibodies Targeting Protein Modifications 
 
Dan Li 
 
 
B.S., Tianjin University, China, 2014 
 
 
 
 
 
 
 
A Dissertation 
Submitted in Partial Fulfillment of the 
Requirements for the Degree of 
Doctor of Philosophy 
at the 
University of Connecticut  
 
2019 
 
  
 ii 
Copyright by 
Dan Li 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2019 
 
  
 iii 
Doctor of Philosophy Dissertation 
Engineering Affinity and Specificity of Antibodies Targeting Protein Modifications 
 
Presented by 
Dan Li, B.S. 
 
 
Major Advisor _________________________________________________________________ 
     Dr. Yongku Cho 
 
Associate Advisor ______________________________________________________________ 
     Dr. Guoan Zheng 
 
Associate Advisor ______________________________________________________________ 
     Dr. Xudong Yao 
 
Associate Advisor ______________________________________________________________ 
     Dr. Yu Lei 
 
 
 
 
University of Connecticut 
2019 
 
  
 iv 
First of all, I would like to thank my major advisor, Dr. Yongku Cho for the opportunity to learn 
and study in his lab at UConn. The amount of patience and effort he was able to exhibit with 
regard to my study and research is astounding. Our weekly discussions were always productive 
and continually pushed me in the right direction. I thank him for helping my writing and 
presentation skill, as well as my professional thinking. The work in this dissertation would not 
have been possible without his guidance and support. I am so proud to have the opportunity to 
work for him, be mentored by him, and I will look back on our work together fondly. 
I would like to thank my associate advisors: Dr. Guoan Zheng, Dr. Xudong Yao and Dr. Yu Lei, 
for their time and valuable guidance on my dissertation. I am also very thankful to Dr. Xudong 
Yao and Dr. Benjamin Wolozin for their scientific input, kindness and time they dedicated to our 
collaboration and research. 
I am sincerely grateful to have worked with my lab mates: Shiyao Wang, Azady Pirhanov and 
Monika Arbaciauskaite. It has been wonderful to see you and work with you in Dr. Cho’s lab. I 
thank you all for both your professional and emotional support in the past. I also want to thank 
all of my friends, both at UConn and elsewhere who made my life here pleasant and enjoyable. 
In the end, I would like to acknowledge my family: my mom and my brother. Thank you for the 
amount of love, encouragement, and support for my study and life. Without their unconditional 
support, I could not have the chance to get here, to be the person I am today! I can’t express how 
much I miss them at this moment! This work is dedicated to my beloved family. 
 
  
 v 
Table of Contents 
APPROVAL PAGE ..................................................................................................................... iii	
ACKNOWLEDGEMENTS ........................................................................................................ iv	
List of tables.................................................................................................................................. ix	
List of figures ................................................................................................................................. x	
Chapter 1	 Introduction ........................................................................................................... 1	
	 Overview ............................................................................................................................. 1	
	 Research objectives ............................................................................................................. 3	
	 Significance and contributions ............................................................................................ 5	
	 Organization of the thesis ................................................................................................... 7	
	 References ........................................................................................................................... 8	
Chapter 2	 Background and literature review .................................................................... 10	
	 Antibodies targeting protein PTMs ................................................................................... 10	
2.1.1	 Protein PTMs .................................................................................................... 10	
2.1.2	 PTM-specific antibodies ................................................................................... 11	
	 Tau protein ........................................................................................................................ 12	
2.2.1	 Tau PTMs and Alzheimer’s Disease ................................................................. 14	
2.2.2	 Phosphorylation of tau ...................................................................................... 15	
2.2.3	 Commonly used phospho-tau antibodies .......................................................... 16	
2.2.4	 Specificity validation approaches of phospho-tau antibodies ........................... 18	
	 Yeast surface display platform .......................................................................................... 18	
	 References ......................................................................................................................... 21	
 vi 
Chapter 3	 Directed evolution of a picomolar-affinity, high-specificity antibody targeting 
phosphorylated tau ..................................................................................................................... 26	
	 Introduction ....................................................................................................................... 26	
	 Materials and Methods ...................................................................................................... 29	
3.2.1	 Yeast surface display of pT231 scFv ................................................................ 29	
3.2.2	 Peptide modification and purification ............................................................... 30	
3.2.3	 Directed evolution of pT231 scFv .................................................................... 31	
3.2.4	 Purification of pT231 scFvs .............................................................................. 33	
3.2.5	 Fluorescent tagging of purified pT231 scFvs ................................................... 34	
3.2.6	 Immunocytochemistry in HEK 293 cells .......................................................... 34	
3.2.7	 Immunohistochemistry in brain tissue sections ................................................ 35	
	 Results ............................................................................................................................... 36	
3.3.1	 Yeast surface display of a phospho-tau scFv .................................................... 36	
3.3.2	 Chemical labeling of peptides to generate distinctively labeled epitopes ........ 37	
3.3.3	 Verification of binding activity of yeast displayed pT231 scFv ....................... 38	
3.3.4	 Assessment of antibody phospho-specificity using yeast surface display ........ 40	
3.3.5	 Directed evolution of pT231 scFv for improved affinity .................................. 42	
3.3.6	 Characterization of affinity and specificity of scFv mutants ............................ 45	
3.3.7	 Cell and tissue section labeling using purified scFvs ....................................... 48	
	 Discussion ......................................................................................................................... 52	
	 Conclusion ........................................................................................................................ 55	
	 Reference .......................................................................................................................... 57	
 vii 
Chapter 4	 High specificity of widely used phospho-tau antibodies validated using a 
quantitative whole-cell based assay ........................................................................................... 62	
	 Introduction ....................................................................................................................... 62	
	 Materials and Methods ...................................................................................................... 64	
4.2.1	 Cloning of recombinant constructs of tau and mutant tau ................................ 64	
4.2.2	 Cell culture and transfection ............................................................................. 66	
4.2.3	 Tau antibodies ................................................................................................... 66	
4.2.4	 Quantitation of antibody specificity .................................................................. 68	
4.2.5	 Measurement of Φ: validation of phospho-tau antibody specificity ................ 69	
4.2.6	 Immunocytochemistry in HEK293FT cells ...................................................... 71	
4.2.7	 Mouse hippocampus dissection ........................................................................ 71	
4.2.8	 HEK293FT and mouse primary cell lysate preparation and western blotting .. 72	
	 Results ............................................................................................................................... 73	
4.3.1	 Φ: A generalizable parameter for measuring the specificity of phospho-tau 
antibodies .......................................................................................................................... 73	
4.3.2	 Co-expression of glycogen synthase kinase-3b enhances tau phosphorylation 77	
4.3.3	 Quantifying the phospho-site specificity of commonly used phospho-tau 
antibodies .......................................................................................................................... 78	
4.3.4	 Non-specific binding to cells in phospho-tau antibodies .................................. 81	
	 Discussion ......................................................................................................................... 84	
	 Conclusion ........................................................................................................................ 88	
	 References ......................................................................................................................... 90	
Chapter 5	 Conclusion and future perspectives .................................................................. 93	
 viii 
	 Conclusion ........................................................................................................................ 93	
	 Future perspectives ........................................................................................................... 93	
5.2.1	 Avidity effect on antibody screening assay ...................................................... 93	
5.2.2	 Application of binding proteins in optogenetics ............................................... 97	
	 Reference ........................................................................................................................ 112	
 
 
  
 ix 
Table 4.1 Primers for Golden Gate assembly of plasmids ............................................................ 65	
Table 4.2 Primers used for site-directed mutagenesis .................................................................. 65	
Table 4.3 Phospho-tau antibodies ................................................................................................. 67	
 
  
 x 
Figure 2.1 Antibody-phosphopeptide interaction revealed by X- ray crystallography ................ 12	
Figure 2.2 The transcription, alternative splicing and PTMs of tau. ............................................ 13	
Figure 2.3 Putative phosphorylation sites on tau protein and epitopes specific for major tau 
antibodies ...................................................................................................................................... 16	
Figure 2.4 A schematic overview of scFv scaffold displayed on the surface of yeast ................. 20	
Figure 3.1 Schematic representation of antibody specificity quantification using yeast surface 
display ........................................................................................................................................... 37	
Figure 3.2. Modified peptides purification and confirmation ....................................................... 38	
Figure 3.3 Binding activity of yeast displayed pT231 scFv ......................................................... 39	
Figure 3.4 Assessment of CDR mutations on phosphopeptide binding of yeast displayed pT231 
scFv ............................................................................................................................................... 40	
Figure 3.5 Assessment of the specificity of yeast displayed pT231 scFv .................................... 41	
Figure 3.6 Directed evolution of yeast displayed pT231 scFv variants with improved affinity .. 43	
Figure 3.7 Amino acid sequence of individual mutants isolated from the screen for improved 
affinity ........................................................................................................................................... 44	
Figure 3.8 High occurrence mutations identified from the screen mapped on WT pT231 scFv 
structure ......................................................................................................................................... 45	
Figure 3.9 Characterization of affinity and specificity of individual scFvs ................................. 47	
 xi 
Figure 3.10 Confocal microscopy images of HEK293FT cell labeled using purified pT231 scFvs
....................................................................................................................................................... 49	
Figure 3.11 Quantification of cell labeling fluorescence intensity using purified pT231 scFvs .. 50	
Figure 3.12 Tissue labeling using purified pT231 scFvs .............................................................. 51	
Figure 4.1 A ratiometric assay to quantify the specificity of phospho-tau antibodies. ................ 74	
Figure 4.2 Validation of the assay using well characterized anti-tau antibodies .......................... 76	
Figure 4.3 Measurement of Φala and ΦλPP of phospho-tau antibodies. ..................................... 77	
Figure 4.4 Co-expression of GSK-3b in HEK293FT cells enhances phosphorylation of tau. ..... 78	
Figure 4.5 Specificity measurements for commonly used phospho-tau antibodies ...................... 81	
Figure 4.6 Flow cytometry plots showing binding of isotype-matching control antibodies under 
the specificity quantification assay conditions ............................................................................. 82	
Figure 4.7 Non-specific binding to HEK293FT cells in phospho-tau antibodies ......................... 84	
Figure 5.1 Schematic of the Streptavidin-biotin interaction ......................................................... 96	
Figure 5.2 Schematic of yeast surface display formats ................................................................. 97	
	
	 	
 1 
 
 Overview 
Antibodies that target post-translationally modified proteins are widely used in biology and 
clinical investigations. Antibodies exist that can recognize a single modified amino acid (e.g., 
phosphorylated tyrosine) within the context of diverse nearby amino acid sequence (1,2). 
However, most widely used are antibodies binding to a modification site in a defined target 
protein sequence, herein referred to as post-translational modification (PTM)-specific antibodies. 
Due to the large number of experimentally identified post-translational modification sites (> 
87,000) (3), the demand for PTM-specific antibodies continue to grow. Due to the dynamic and 
heterogeneous nature of PTMs, the affinity and specificity of PTM-specific (4) antibodies are 
critical for sensitive and reproducible detection of PTMs (5). Only a fraction of a protein is 
modified at any given time, and the dynamics may vary within a tissue across different cell types 
(6-8). Therefore, PTM-specific antibodies should interact only with the modified target site, with 
high affinity to capture potentially a small fraction of the modified form. 
However, generating high affinity antibodies with high PTM-specificity remains to be 
challenging. Existing methods for generating PTM-specific antibodies rely on immunization 
approaches, but often fail or produce low affinity antibodies. This is due to the fact that the 
peptide epitopes containing PTMs are weak immunogens in mice (9), PTMs undergo rapid 
degradation in vivo regardless of the immunization route (10), and that B-cell response shows an 
affinity ceiling (11,12). Therefore, screening recombinant antibody libraries in vitro is thought to 
be a promising alternative. However, in vitro library screening strategies for PTM-specific 
antibodies also tend to result in low affinity antibodies (Kd ~ 100 nM to µM range) (13-15). This 
trend has been observed for screening phospho-specific antibodies, but it extends to antibodies 
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targeting other PTMs, such as sulfotyrosine (16). The specificity of PTM-specific antibodies is 
recently gaining attention as a critical factor. In case of the microtubule-associated protein tau, 
although phospho-specific antibodies are highly sought after for many target proteins, often at 
multiple phosphorylation sites, they are currently available in limited cases, and often suffer 
from poor specificity and low affinity (17-19). 
High affinity and specificity antibodies against phosphorylated tau will enable the detection in 
low concentration samples. This would be a major factor in developing diagnostic assays using 
patient samples such as cerebrospinal fluid (CSF). Recent studies show that majority of existing 
monoclonal antibodies cannot detect phosphorylated tau, due to low affinity. Affinity of 
antibodies that recognize PTM tau is also an important factor in developing passive 
immunotherapy strategies. Studies in mouse models have shown that for certain tau epitopes, 
targeting antibody affinity is not a major factor, while for antibodies targeting soluble tau affinity 
was highly correlated with efficacy (20). High affinity antibodies against phosphorylated tau will 
be necessary for systematic studies to determine key factors to efficacy. 
This work focuses on the development of assays for generating and characterizing PTM-specific 
antibodies with high specificity and affinity. To assess the specificity of PTM-targeting 
antibodies, we develop an experimental approach based on yeast surface display to quantify 
single-chain variable fragment (scFv) binding against a defined set of structurally similar 
epitopes. We generate a picomolar affinity scFv targeting phosphorylated T231 of human tau 
using directed evolution. The yeast surface display approach allows specificity measurement 
when the sequence of the antibody is known, which makes it useful for screening antibody 
variants. However, for many antibody users, the assay is not readily applicable for measuring 
specificity, since the antibody sequence information may be unavailable. Therefore, we report a 
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robust flow cytometry assay using human embryonic kidney (HEK) cells that enables the 
determination of a specificity parameter termed Φ, which measures the fraction of non-specific 
signal in antibody binding. We apply our assay to measure the specificity of 7 widely used 
phospho-tau antibodies (AT270, AT8, AT100, AT180, PHF-6, TG-3, and PHF-1) among others. 
 
 Research objectives 
It is the aim of this work to engineer and assess affinity and specificity of antibodies targeting 
protein PTM, particularly in tau phosphorylation. The objective of this research can be broken 
down into 2 aims:  
(1) Develop a screening assay to generate high-affinity and specific PTM-specific antibody using 
yeast surface display. According to the x-ray crystal structural of antibody-phosphoepitope 
complex, it’s plausible that high-affinity phospho-specific antibodies selectively stabilize either 
the peptide sequence or phosphate interactions, leading to increase in cross reactivity towards the 
non-phosphoepitope or irrelevant phosphorylation sites. Therefore, we hypothesized that a trade-
off between affinity and specificity might exist in PTM-specific antibodies. To test this 
hypothesis, we sought to assess the impact of in vitro affinity maturation on the specificity of 
PTM-targeting antibodies. 
The specific aims of this project were: 
i. Development of an assay to quantify specificity of phospho-specific antibody using 
yeast surface display 
• Yeast surface display of a phospho-tau-specific scFv 
• Chemically labelling peptides to generate distinctively labeled epitopes 
• Assessment of scFv phospho-specificity using yeast surface display 
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ii. Engineering antibody phospho-specificity and affinity through directed evolution 
• Creation of a yeast displayed scFv library using random mutagenesis and DNA shuffling 
• Affinity maturation of yeast displayed scFvs using FACS 
iii. Characterization of affinity and specific of scFv mutants 
• Validation of scFv mutants using yeast surface display 
• Testing the good performing scFv mutants in cell and tissue section labeling 
In summary, the outcomes of this project were: introducing a yeast surface display approach to 
quantify the specificity of PTM-specific antibodies, and developed a screening assay based on it 
to generate PTM-specific antibodies with improved affinity and high specificity through directed 
evolution. 
(2) Introduce a quantitative whole-cell based assay to validate PTM-specific antibody specificity. 
Antibodies binding to phosphorylated tau (phospho-tau) are extensively used in research and 
being adopted in clinical diagnosis. However, few validation data have been published and 
existing specificity characterization methods relied on immunoblotting approaches which are not 
ideal for quantitative measurement due to frequent signal saturation in immunoblotting 
experiments. To fill this critical need, we introduced a parameter termed Φ that quantifies 
specificity of phospho-tau antibodies and established a generalizable, robust assay to measure it. 
The specific aims of this project were: 
i. Development of a whole-cell based approach to quantify phospho-tau antibody 
specificity using flow cytometry 
• HEK293 cells expressing fluorescent tagged full-length tau 
• Validation of the assay using previously characterized anti-tau antibodies 
• Defining a parameter Φ to quantitatively measure the specificity phospho-tau antibodies 
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ii. Quantifying the phospho-specificity of commonly used phospho-tau antibodies 
• Measurement of specificity Φ of commonly used phospho-tau antibodies using flow 
cytometry 
• Assessment of non-specific binding in phospho-tau antibodies by performing cell 
labeling and western blotting 
In summary, the outcomes of this project were: providing a whole-cell based approach to 
validate the specificity of phospho-tau antibodies, and determined a parameter Φ for phospho-tau 
antibodies based on it, that enable quantitative comparison of specificity. We anticipate that this 
parameter will be widely adopted in guiding users of the specificity of phospho-tau antibodies, 
and potentially PTM-specific antibodies in general. 
 
 Significance and contributions 
High quality antibodies require high specificity and affinity toward the targets. The specificity 
and affinity of PTM-specific antibodies are critical for sensitive and reproducible detection of 
protein PTM. However, the current methods for generating PTM-specific antibodies have 
drawbacks that make is hard to identify high quality antibodies; and many PTM-specific 
antibodies have low affinity and poor specificity. This work improved the success rate of 
generating high quality PTM-specific antibodies, and provided an assay to quantitatively 
measure the specificity of those antibodies. 
This work allows for contributions in the following fields: 
i. Introduced a yeast surface display approach to quantify antibody specificity 
ii. Developed a screening assay to generate antibodies with improved affinity and high 
specificity using yeast surface display 
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iii. Generated a pico-molar affinity scFv targeting phosphorylated T231 of human tau using 
directed evolution 
iv. Provided information on structure analysis of antibody-antigen interaction 
v. Enabled small binders in cell and tissue staining 
vi. Developed a whole-call based approach to quantitatively quantify the specificity of PTM-
specific antibodies 
vii. Introduced a parameter Φ to measure the specificity of PTM-specific antibodies, which 
will be widely adopted in guiding the use PTM-specific antibodies in general 
 
Manuscripts and publications have been resulted from this work as listed below: 
1. Li, D., Cho, Y.K.*, High specificity of widely used phospho-tau antibodies validated 
using a quantitative whole-cell based assay, in revision, 2019 
2. Li, D., Wang, L., Maziuk, B.F., Yao, X., Wolozin, B., Cho, Y.K.*, Directed evolution of 
a picomolar affinity high-specificity antibody targeting phosphorylated tau, Journal of 
Biological Chemistry, 2018, 293, 12081-12094 
3. Knowlton, S., Li, D., Ersoy, F., Cho, Y.K.*, Tasoglu S.*, Building Blocks for Bottom-
Up Neural Tissue Engineering: Tools for In Vitro Assembly and Interrogation of Neural 
Circuits (book chapter), Neural Engineering, 2016 
4. Cho, Y.K.*, Li, D., Optogenetics: Basic Concepts and Their Development (book chapter), 
Methods in Molecular Biology, 2016 
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 Organization of the thesis 
Chapter 2 provides an overview of the background, concepts and significances of PTM-specific 
antibodies. It begins with a brief introduction of protein PTMs and the antibodies that targets 
such antigens. Antibodies targeting tau PTMs are highlighted, specifically discussing the 
antibodies targeting phosphorylated tau that is associated with Alzheimer’s Disease. In the end of 
this chapter, we review a yeast surface display technique, that is vital in in vitro recombinant 
antibody screening assays. 
In Chapter 3, we introduce an approach using yeast surface display to quantify the specificity of 
phospho-specific antibodies. We develop a screening assay based on it to generate PTM-specific 
antibodies with improved affinity and high specificity. We demonstrate that in vitro affinity 
maturation leads to cross-reactivity in PTM-specific antibodies. However, quantifying the 
specificity allows identifying an antibody with improved affinity and specificity. 
In Chapter 4, we provide a whole-cell based approach to validate the specificity of phospho-tau 
antibodies. We introduce the parameter Φ for phospho-tau antibodies, that enable quantitative 
comparison of specificity. Using our assay, we quantified the specificity Φ of 7 widely used 
phospho-tau antibodies (AT270, AT8, AT100, AT180, PHF-6, TG-3, and PHF-1) as well as 2 
additional phospho-tau antibodies (1H6L6 and pS404). 
Chapter 5 presents a summary of this work and provides the future perspectives of this work. 
First, we will assess the avidity effect of the yeast surface displayed scFvs for the targets, and 
apply it in developing a novel in vitro screening assay. Second, we will develop small binding 
protein for tau, combined with optogenetics tools allows the visualization of complex structures 
such as synapse. 
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 Antibodies targeting protein PTMs 
Antibodies that target proteins post-translation modifications (PTMs) are widely used in biology 
and clinical investigations. Some antibodies can bind to a single modified amino acid (e.g., 
phosphorylated tyrosine) within the context of diverse nearby peptide sequences (1,2). However, 
most widely used are antibodies specific to a modification site in a defined target protein 
sequence, herein referred to as PTM-specific antibodies. Due to a large number of 
experimentally identified post-translational modification sites (> 87,000) (3), the demand for 
PTM-specific antibodies continues to grow. 
2.1.1 Protein PTMs  
In the last few decades, researchers discovered that the human proteome is more complex than 
human genome. The increase of the complexity of proteome to genome is facilitated by many 
different mechanisms, including PTMs. PTM is covalent and enzymatic modification of proteins 
following protein biosynthesis. It occurs after the mRNA is translated into the protein sequence 
in ribosomes. PTMs process the protein by adding different biochemical group (such as 
phosphorylation, methylation), or adding different small protein molecule (such as 
ubiquitination), or splicing protein sequence at specific sites. PTM is involved in nearly all 
aspect of biological, and plays important role in regulating protein level and function. For 
instance, phosphorylation, which is the most common PTM, alters biological activity of enzymes 
(3). Many enzymes and receptors are switched "on" or "off" by phosphorylation and 
dephosphorylation. 
PTM is a key mechanism that enables reversible regulation of protein activity, conformation, 
localization, turnover rate, and interactions. Abnormal PTMs result in dysregulation of these 
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processes and are often associated with pathological conditions, including heart disease, cancer, 
and neurodegeneration (4-8). In case of tau protein, numerous abnormal PTMs regulate its 
biology, and are associated with several neurodegenerative diseases including Alzheimer’s 
Disease (AD), collectively referred to as tauopathies (9). 
2.1.2 PTM-specific antibodies 
Since protein PTMs are included in many pathological conditions, detection of protein PTMs is 
valuable in identifying the cause and tracking the progression of these diseases. However, robust 
detection of PTMs is challenging due to their dynamic and heterogeneous nature. Only a fraction 
of a protein is modified at any given time, and the dynamics may vary within a tissue across 
different cell types (10-12). Therefore, the affinity and specificity of PTM-specific antibodies are 
critical for sensitive and reproducible detection of PTMs (13). PTM-specific antibodies should 
interact only with the modified target site, with high affinity to capture potentially a small 
fraction of the modified form. 
Recently, an x-ray crystal structure of an antibody in complex with a phosphoepitope peptide of 
tau (PDB code 4GLR) revealed a recognition motif, in which a sector of residues from the 
complementarity determining region (CDR)-H2 interact with the phosphate group of 
phosphorylated threonine 231of tau and another sets of CDR residues contacting the peptide 
sequence (Figure 2.1) (14). Such distinct recognition sectors were also found in structural 
analyses of other phospho-specific antibodies (15). 
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Figure 2.1 Antibody-phosphopeptide interaction revealed by X- ray crystallography 
The interaction is mediated by recognition of the phosphate group by CDR-H2 (solid) and the surrounding 
residues by other CDRs(dashed). Image generated based on PDB code 4GLR. 
 
In case of tau PTM-specific antibodies, their affinity and specificity are particularly important, 
since they dictate their efficacy in a wide range of applications. High-affinity antibodies are 
superior in detecting tau PTMs from clinical samples (16), but mouse model experiments suggest 
that high specificity antibodies may be more beneficial for passive immunotherapy targeting tau 
(17). 
 
 Tau protein 
Tau is a microtubule-associated protein tau (MAPT) which are found mostly in neurons. Its 
major functions are to promote microtubule assembly and maintain the stability of the neurons 
through binding to the microtubules. Tau has two ways to control microtubule stability: tau 
isoforms and tau phosphorylation. 
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Human MAPT gene for encoding tau protein is located on the human chromosome 17q21, 
having 16 exons (18). Alternative splicing of exons 2,3 and 10 leads to formation of six tau 
isoforms which are composed of 352 - 441 amino acid residues with molecular weight of ~ 37 - 
46 kDa (Figure 2.2) (19,20). Tau isoforms contain either 0, 1 or 2 inserts of 29 amino acids at 
the N-terminus (exon 2 and 3), and 3 or 4 microtubule-binding repeats at the C-terminus (exon 
10). Six isoforms of tau have been found in adult human brains (21). 
 
Figure 2.2 The transcription, alternative splicing and PTMs of tau.  
By transcription and alternative splicing at exons 2, 3 and 10 of tau mRNA, six isoforms of tau protein are 
generated from a single gene located on the chromosome 17q21 in human. Different tau isoforms are named 
according to the numbers of the N-terminal inserts and/or C-terminal microtubule-binding domain (such as 
2N4R) or according to the clones (such as Tau40) (19). 
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2.2.1 Tau PTMs and Alzheimer’s Disease 
The complexity of the tau isoforms can be further increased by PTMs (Figure 2.2). During 
normal development, tau protein undergoes various PTM, including phosphorylation, 
glycosylation, acetylation, ubiquitination, truncation etc. Recent studies suggest that the PTMs of 
tau may participate in the regulations of intracellular signal transduction, development and 
viability of the neurons (22). 
The abnormal PTM, such as hyper-phosphorylation, has been found in a number of 
neurodegenerative disorder, known as tauopathy, such as AD, corticobasal degeneration, Down’s 
syndrome. Phosphorylation sites at or near the repeat elements of the microtubule binding 
domains are particularly important for the pathophysiology of tauopathy (23). An increase in tau 
phosphorylation, on average from 2 - 3 to 7 - 8 phosphate per molecule (23) results in 
preferential phosphorylation at sites that decrease microtubule binding (24,25), and increases its 
propensity to form oligomers and high order aggregates (23,26). Levels of tau oligomers showed 
a strong correlation with memory loss in a mouse model of tauopathy (27). Acetylation at 
specific lysine residues interferes with ubiquitination and subsequent degradation by the 
proteasome, resulting in accumulation of phosphorylated tau and associated toxicity in mouse 
models (28-31). 
The tau hypothesis states that, in AD brains, tau becomes hyperphosphorylated, resulting in 
reduced affinity for microtubules and self-aggregating into paired helical filament (PHF), leading 
to formation of neurofibrillary tangles (32,33). This process causes the microtubules 
depolymerisation, and finally breaks the neurons. Therefore, these phosphorylated neurofibrillary 
tangles are often seen in AD brain and thought to be a hallmark of AD. 
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AD is a progressive neurodegenerative disease, it’s the most well-known form of dementia, 
accounting for 50-60% of all cases (34). AD patients often suffer from memory loss, confusion 
and behavioral issues. Gradually, bodily functions are lost, ultimately leading to death. In 2018, 
50 million people have dementia in worldwide, and there will be one new case every 3 second, 
so that more than 150 million people will live with dementia by 2050. In 2018 the global societal 
cost of dementia is 1 trillion US dollars, and it will rise to 2 trillion by 2030. Until now, there are 
no drugs available that can prevent or even slower this course. 
2.2.2 Phosphorylation of tau 
On the basis of tau hypothesis, abnormal PTM of tau is currently the most common disease-
modifying target. Among these PTMs, tau phosphorylation is the most common and the best-
studied. In AD brains, the level of the hyper-phosphorylated tau is 3-4 fold higher than that of 
tau isolated from normal brains (35,36). There are 85 serine, threonine, or tyrosine 
phosphorylation sites in the longest human brain tau isoform, and 45 sites have been identified in 
AD brain samples by using mass spectra or antibodies recognition (Figure 2.3) (37,38). And 
they are clustered in the proline-rich domain (PRD) and C-terminal region of tau.  
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Figure 2.3 Putative phosphorylation sites on tau protein and epitopes specific for major tau antibodies 
Red color denotes amino acids phosphorylated in AD brain, green in both AD and normal brain, blue in 
normal brain, while black color means that those phosphorylation sites have not been fully characterized yet. 
Tau antibodies specific for phospho-tau epitopes are given in purple, while pink color denotes antibodies 
specific for non-phosphorylated tau epitopes (38). 
 
2.2.3 Commonly used phospho-tau antibodies 
Antibodies targeting tau phosphorylation (phospho-tau) are extensively used in research and 
being adopted in clinical diagnosis (39-44). According to antibody databases (Antibodypedia and 
Alzforum), thousands of anti-tau antibodies are currently available, including >180 unique 
phospho-tau antibodies. Epitopes recognized by some commonly used phospho-tau and 
nonphospho-tau antibodies are shown in Figure 2.3 (38). 
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AT270. This antibody is against phosphorylated epitope T181(45,46), which is in PRD of tau. 
AT270 is produced using PHF tau as the immunogen, and it does not recognize recombinant tau, 
but does so after phosphorylation with brain extract. 
AT8. This antibody is against phosphorylation epitope S199 and/or S202 and/or T205 (45,46), 
which are in PRD of tau. Previous study has shown that AT8 recognition requires only S202 to 
be phosphorylated in tau (47). AT8 recognizes all isoforms of PHF tau but not tau from normal 
mammalian brain, thus the antibody is specific for the Alzheimer state and has the advantage of 
reporting on the state of phosphorylation (48). 
AT100. This antibody is against doubly phosphorylated epitope T212/S214 (49-52), which are in 
PRD of tau. AT100 epitope is formed only when a specific order of phosphorylation occurs (53). 
It has also been shown that Thr212 and Ser214 are sequentially phosphorylated by glycogen 
synthase kinase 3β (GSK-3b) and protein kinase A (PKA), respectively (53). 
AT180. This antibody is against phosphorylated epitope T231 (45,51,54), which is in PRD of tau. 
AT180 is produced using PHF tau as the immunogen, and it does not recognize recombinant tau, 
but does so after phosphorylation with brain extract. 
PHF6. This antibody is against phosphorylated epitope T231 (55,56), which is in PRD of tau. 
PHF6 recognizes PHF tau containing phosphorylated T231. 
TG-3. This antibody is sensitive to the conformation changes of phosphorylated Thr231, which 
is in PRD of tau, it recognizes neurofibrillary tangles of tau in AD, while not reacts to normal tau 
(51,57,58).  
PHF1. This antibody is against doubly phosphorylated epitope S396/S404 (50,59,60), which are 
in C-terminal region of tau. PHF1 recognizes PHF tau containing either individually 
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phosphorylated S396 or S404, but is more sensitive in detection when both serines are 
phosphorylated. 
2.2.4 Specificity validation approaches of phospho-tau antibodies 
Recent studies have shown that some phospho-tau antibodies lack specificity (61-63). Existing 
specificity characterization methods relied on immunoblotting approaches using either synthetic 
peptides, cell lysates or extracted PHF tau (61-63). Synthetic peptides allow binding 
measurement to exactly defined phosphorylation sites, but is prohibitively costly to cover all 
phospho-sites across the full-length tau. Cell lysates allow detection of non-specific binding to 
non-tau proteins (61), but cannot measure cross-reactivity to non-modified tau or other 
phosphorylation sites. Extracted PHF-tau from AD brain homogenates allows characterizing 
antibodies that do not recognize normal human adult tau and measuring the cross-reactivity to 
nonphospho-tau by treatment with phosphatase, but cannot capture the phospho-site specificity 
(63). Steinhilb and colleagues have generated transgenic flies expressing tau with alanine point 
mutations at several serine-proline and threonine-proline motifs of human tau (64). In this study, 
they used fly head extracts from these transgenic lines to perform western blotting using 
phospho-tau antibodies. In principle, this approach may be applied for validating phospho-tau 
antibodies. However, all of these approaches are not ideal for quantitative measurement due to 
frequent signal saturation in immunoblotting experiments (65). 
 
 Yeast surface display platform 
Yeast surface display is a powerful method for isolating and engineering antibodies to increase 
their affinity and specificity (66). Yeast surface display has been used to engineer antibodies 
targeting several proteins, including T cell receptors (67), botulinum neurotoxin (68), and 
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huntingtin protein (69). Yeast display libraries, which has 107-109 transformants, are smaller than 
phage or ribosome display libraries, which is 1011-1013, but have many advantages of eukaryotic 
expressed proteins. They have eukaryotic expression, processing, and secretory pathway, which 
suggest more complex PTMs of proteins (70). 
In the yeast surface display system (Fig. 2.4), the antibody is displayed as a single chain variable 
fragment (scFv) in which the heavy and light variable chains are connected by a flexible 
polypeptide linker (Gly4Ser)3. The scFv is fused to the C-terminal end of agglutinin Aga2 protein, 
which forms two disulfide bonds to the agglutinin Aga1 protein on the yeast surface. Both Aga1 
and Aga2 protein are controlled under a galactose-inducible promoter. Each yeast cell displays 
40,000-50,000 scFvs (66,71), and can be detected through immunofluorescence labeling of either 
the c-myc or the hemagglutinin (HA) epitope tag flanking the scFv. The binding to an antigen of 
interest can be detected by labeling the yeast cell with antigen and a secondary reagent 
conjugated with fluorophore. Yeast surface display library enables quantitative screening using 
fluorescence-activated cell sorting (FACS), and the antigen binding signal can be normalized for 
expression, eliminating impacts due to host expression bias. 
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Figure 2.4 A schematic overview of scFv scaffold displayed on the surface of yeast 
The scFv is C-terminal fusion to the Aga2 and flanked by two epitopes: HA at the N-terminus and c-Myc at 
the C-terminus. The Aga2p forms two disulfide bonds with the Aga1p, which is anchored to the cell wall. 
Antigen binding is detected with a fluorophore FITC. Display of scFv is detected with a primary mouse anti-c-
Myc antibody and a phycoerythrin-conjugated mouse secondary antibody (66). 
 
Once the candidate scFvs are isolated from the library, they are engineered for improved affinity 
and specificity (72) using random mutagenesis through error-prone PCR with nucleotide analogs 
(73). The mutation frequency can be controlled by altering the number of PCR cycles and the 
amount of nucleotide analogs. In addition, DNA shuffling (74,75) can be used to introduce 
diversity into the library. The mutagenized library is created by transformation of yeast cells with 
the mutated products and linearized vector through homologous recombination in yeast (75). 
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 Introduction 
Antibodies that target post-translationally modified proteins are widely used in biology and 
clinical investigations. Some antibodies can bind to a single modified amino acid (e.g., 
phosphorylated tyrosine) within the context of diverse nearby peptide sequences (1,2). However, 
most widely used are antibodies specific to a modification site in a defined target protein 
sequence, herein referred to as PTM-specific antibodies. Due to a large number of 
experimentally identified post-translational modification sites (3), the demand for PTM-specific 
antibodies continues to grow.  
PTM is a key mechanism that enables reversible regulation of protein activity, conformation, 
localization, turnover rate, and interactions. Abnormal PTMs result in dysregulation of these 
processes and are often associated with pathological conditions. In case of the microtubule-
associated protein tau, numerous abnormal PTMs regulate its biology, and are associated with 
several neurodegenerative diseases including AD, collectively referred to as tauopathies (4). Tau 
contains 85 putative phosphorylation sites (5) and 14 putative acetylation sites (6). 
Phosphorylation sites at or near the repeat elements of the microtubule binding domains are 
particularly important for the pathophysiology of tauopathy (7). An increase in tau 
phosphorylation, on average from 2-3 to 7-8 phosphate per molecule (7) results in preferential 
phosphorylation at sites that decrease microtubule binding (8,9), and increases its propensity to 
form oligomers and high order aggregates (7,10). Levels of tau oligomers showed a strong 
correlation with memory loss in a mouse model of tauopathy (11). Acetylation at specific lysine 
residues interferes with ubiquitination and subsequent degradation by the proteasome, resulting 
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in accumulation of phosphorylated tau and associated toxicity in mouse models (12-15). 
Therefore, detection of tau PTMs at specific sites is valuable in identifying the cause and 
tracking the progression of tauopathies. 
However, robust detection of PTMs is challenging due to their dynamic and heterogeneous 
nature. Only a fraction of a protein is modified at any given time, and the dynamics may vary 
within a tissue across different cell types (16-18). Therefore, the affinity and specificity of PTM-
specific antibodies are critical for sensitive and reproducible detection of PTMs (19). PTM-
specific antibodies should interact only with the modified target site, with high affinity to capture 
potentially a small fraction of the modified form. In case of tau PTM-specific antibodies, their 
affinity and specificity are particularly important, since they dictate their efficacy in a wide range 
of applications. High-affinity antibodies are superior in detecting tau PTMs from clinical 
samples (20), but mouse model experiments suggest that high specificity antibodies may be more 
beneficial for passive immunotherapy targeting tau (21).  
Even though many PTM-specific antibodies exist, high-affinity antibodies with high PTM-
specificity are rarely found. Rodent immunization approaches often fail or produce low-affinity 
antibodies. This is because the peptide epitopes containing PTMs are weak immunogens in mice 
(22), PTMs undergo rapid degradation in vivo regardless of the immunization route (23), and B-
cell response shows an affinity ceiling (24,25). Screening recombinant antibody libraries in vitro 
is a promising alternative. However, in vitro library screening strategies tend to generate PTM-
specific antibodies with a low or moderate affinity (Kd ~ µM to 100 nM range) (26-29).  
Obtaining high specificity antibodies targeting PTMs is even more challenging.  In fact, many 
commercially available PTM-specific antibodies have not been validated for their specificity. 
Recent evidences using various approaches, including immunoassays using synthetic peptides 
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and peptide arrays, have shown that indeed a significant fraction of existing PTM-targeting 
antibodies lack specificity (30-34). These studies have identified major species that non-
specifically bind to the antibodies, including non-modified epitopes with the target amino acid 
sequence and those with modifications at non-target sites (31,34).  
Recently, X-ray crystal structures of phospho-specific antibodies have revealed a key insight on 
how PTM-targeting antibodies may gain specificity (26,27). In these antibodies, a set of 
complementarity determining region (CDR) residues were found to interact with the phosphate 
group, while others make contacts with the amino acid residues nearby, leading to recognition of 
both the modification and target sequence. Therefore, balancing the stability of interaction of 
these distinct sets of CDR residues seems to be important in gaining both the affinity and 
specificity. It is plausible that high-affinity PTM-targeting antibodies can achieve such tight 
binding by stabilizing the interaction towards either the modified amino acid or peptide sequence, 
potentially leading to unwanted cross-reactivity. Therefore, we hypothesized that a trade-off 
between affinity and specificity might exist in PTM-targeting antibodies. 
To test this hypothesis, we sought to assess the impact of in vitro affinity maturation on the 
specificity of PTM-targeting antibodies. Starting from an existing high-specificity antibody (27) 
targeting phosphorylated T231 of human tau (pT231, numbering based on the 441 amino acid 
2N4R isoform), we generated a single-chain variable fragment (scFv) and improved its affinity 
using directed evolution. To assess the specificity of PTM-targeting antibodies, we developed an 
experimental approach based on yeast surface display (35) to quantify scFv binding against a 
defined set of structurally similar epitopes. Specifically, peptides representing the 
phosphorylated epitope, non-phosphorylated epitope, or a phosphorylated epitope with the same 
amino acid composition, but scrambled sequence were labeled for detection. Their interactions 
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with yeast displayed antibody fragments were quantified using flow cytometry. Indeed, the 
original high-specificity phospho-tau scFv showed nearly perfect specificity in this assay, in 
agreement with previous characterizations (27). We found that through directed evolution, the 
affinity could be improved by > 20-fold, reaching picomolar monovalent dissociation constants. 
However, the majority of affinity-improved scFvs showed significant non-specific binding to the 
non-phosphorylated epitope but not to the scrambled phospho-epitope, suggesting that high-
affinity clones tend to gain affinity by stabilizing the interaction with the amino acid residues 
surrounding the modification site. Even though the majority of clones showed a trade-off 
between their affinity and specificity, this was not necessarily the case for some unique clones. 
By assessing the binding specificity, we identified a picomolar-affinity clone with specificity 
profiles that match the original high-specificity antibody. These results demonstrated that a 
quantitative assessment of both affinity and specificity was critical for identifying high affinity 
and specificity antibodies targeting PTMs. 
 
 Materials and Methods 
3.2.1 Yeast surface display of pT231 scFv 
Amino acid sequence of VL and VH from an anti-tau pT231 antibody (27) was back-translated 
to DNA sequence, yeast-codon optimized and synthesized (Integrated DNA Technologies). A 
(G4S)3 linker was inserted between the VL and VH sequences (5’-VL-linker-VH) to create a 
fusion construct encoding a scFv sequence. The synthesized scFv gene was cloned using PCR to 
add a 5’ NheI and a 3’ BsrGI (New England Biolabs) restriction sites. The PCR products were 
ligated into the vector pCT4RE (35) (a gift from Dr. Eric Shusta). This plasmid included an N-
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terminal c-myc epitope tag and a C-terminal FLAG epitope tag. The pCT4RE plasmid was 
transformed into S. cerevisiae EBY100 (35) (a gift from Dr. Dane Wittrup). 
3.2.2 Peptide modification and purification 
All peptides used were purchased from a commercial source (Peptide 2.0). Peptides contained a 
C-terminal cysteine for chemical modification. Peptides to be modified were dissolved at 1 mM 
in phosphate-buffered saline (PBS, 8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4, 0.24 g/L 
KH2PO4, pH 7.4) at room temperature. A 10 mM stock solution of Alexa Fluor 488 C5 
maleimide (Thermo Fisher Scientific) was prepared in deionized H2O, and a 100 mM stock 
solution EZ-link maleimide-PEG11-biotin (Thermo Fisher Scientific) was prepared in dimethyl 
sulfoxide (DMSO). The Alexa Fluor 488 C5 maleimide stock solution was protected from light 
by wrapping container with aluminum foil. For peptide modification, either Alexa Fluor 488 C5 
maleimide or EZ-Link maleimide-PEG11-biotin stock solution was added to the peptide PBS 
solution at a final reagent concentration of 2 mM. The reactions proceeded at 4 oC overnight in 
the dark. 
Modified peptides were purified using an HPLC system (Shimadzu SCL-10Avp), equipped with 
a preparative column (Waters, Atlantis T3, 100 Å, 10 µm, 10 mm x 250 mm). For the mobile 
phase, solvent A consisted of 99.9 % H2O and 0.1 % trifluoroacetic acid, and solvent B consisted 
of 99.9 % methanol and 0.1 % trifluoroacetic acid. Solvent flow rate was 3.5 mL/min. The 
column temperature was set at 50 oC. For each HPLC run, 100 µL of the peptide reaction mixture 
was injected. The gradient for peptides was as following: 0 % solvent B at 0 min, 20 % solvent B 
at 1 min, 40 % solvent B at 26 min, solvent 75 % B at 31 min, and 100 % solvent B at 36 min. 
Purified peptide fractions, which were detected at 214 nm, were collected, lyophilized, and 
stored at - 20 oC. 
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Mass spectrometry of the modified peptides was conducted using a QStar Elite hybrid QTOF 
mass spectrometer (AB Sciex). TOF spectra ((300-2000 m/z) were acquired using Analyst QS 
2.0 software. 
3.2.3 Directed evolution of pT231 scFv 
pT231 scFv was randomly mutagenized as described previously (36) with the following 
modifications. Error-prone PCR using a mixture of triphosphates of nucleoside analogs. Each 
PCR consisted of ~ 250 ng of plasmid template, 0.5 µM of forward and reverse primer, 200 uM 
of dNTP mix (Thermo Fisher Scientific), Taq PCR buffer (without MgCl2), 2 mM of MgCl2, 2.5 
units of Platinum Taq DNA polymerase (Thermo Fisher Scientific), 2 µM of 8-Oxo-2'-
deoxyguanosine-5'-triphosphate (Tri-Link Biotechnologies, 8-Oxo-dGTP) and 2 µM of 2'-
Deoxy-P-nucleoside-5'-Triphosphate (Tri-Link, Biotechnologies dPTP) in a 50 µL of reaction 
volume. The mixture was denatured at 94 oC for 3 min followed by 19 cycles of 94 oC for 45 s, 
55 oC for 30 s, and 72 oC for 60 s and a final extension of 72 oC for 10 min on a thermocycler. 
The PCR product was gel-purified using a gel extraction kit (Zymo Research). 2 µL of purified 
mutagenesis product was added to a 100 µL of PCR reaction solution without using nucleoside 
analogs to amplify the mutated fragments. About 6.4 µg of mutated pT231 scFv gene, and 1 µg 
of vector pCT4RE (a gift from Dr. Eric Shusta) were combined with 200 µL of electrocompetent 
EBY 100 (a gift from Dr. Dane Wittrup) and electroporated at 2.5 kV and 25 µF capacitance 
using the GenePulser (Bio-Rad, 0.2 cm Electrode gap cuvette). The electroporated cells were 
grown in SD-CAA media (0.1 M sodium phosphate, pH 6.0, 6.7 g/L yeast nitrogen base, 5 g/L 
casamino acids, 20 g/L glucose) at 30 oC and 250 rpm. Frozen aliquots of the library were 
prepared by freezing 10x library diversity in yeast freezing media (2 % glycerol and 6.7 g/L 
yeast nitrogen base) at - 80 oC for long-term storage. 
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For the following rounds of gene diversification, it was realized by shuffling the library screened 
in the previous round, followed by the above random mutagenesis procedure to incorporate 
additional mutations. The plasmid DNA from the library pool was isolated using a yeast plasmid 
miniprep kit (Zymo Research). pT231 scFv library gene was PCR amplified with primers 
flanking the region. 2-4 µg of the PCR product was digested with 0.0015 unit of DNase I (New 
England BioLabs) per µL in 100 µL of reaction mixture for 15 min at room temperature. 
Fragments of 10-50 bp were purified from 2 % low melting agarose gel by electrophoresis and 
then re-suspended in 50 µL of PCR reaction without primers. A PCR program of 94 oC for 3 min; 
29 cycles of 94 oC for 30 s, 55 oC for 30 s, 72 oC for 30 s, and 72 oC for 10 min was used on a 
thermocycler. Mixtures of DNA fragments were reassembled into a gene at defined positions 
based on gene homology.  
Fluorescence activated cell sorting was used to screen for yeast cells displaying high-affinity 
scFvs. 10x library diversity of cells were pelleted and washed with 1 mL of phosphate-buffered 
saline with bovine serum albumin (PBSA, 8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4, 0.24 g/L 
KH2PO4, 1 g/L bovine serum albumin, pH 7.4) twice. The cells were incubated with Pphos-b in 3 
mL PBSA at room temperature for 1 hour. After labeling with peptide, the cells were primarily 
stained with mouse anti-FLAG (Sigma, 1:1000 dilution) in 1 mL of PBSA on ice for 30 min, and 
then secondarily stained with goat anti-mouse Alexa Fluor 488 (Thermo Fisher Scientific, 1:100 
dilution) and streptavidin R-phycoerythrin (SAPE, Thermo Fisher Scientific, 1:100 dilution) in 1 
mL of PBSA on ice for 30 min. Pelleting and washing the cells with 500 µL of PBSA were 
required between all labeling steps to remove any unbound peptides and antibodies. After 
labeling, the cells were re-suspended in 3 mL of PBSA and treated with 1 µM of unmodified 
phosphopeptide at room temperature for 7 min. The screening was carried out on a Becton-
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Dickinson FACSAria II, which was equipped with five different lasers. Data of cell screening 
was acquired using BD FACSDiva software. The collected cells were grown in SD-CAA media 
plus 1 % kanamycin at 30 oC, 250 rpm overnight. After several rounds of cell propagation, 10x 
library diversity of cells were archived in yeast freezing media at -80 oC.  
3.2.4 Purification of pT231 scFvs 
The pT231 scFv gene was inserted into the vector pRS316 (a gift from Dr. Eric Shusta), which 
had been restriction-digested with NheI and BsrGI (New England Biolabs). This plasmid 
included a C-terminal hexa-histidine epitope tag. The pRS316 plasmid was transformed into S. 
cerevisiae YVH10 cells (37) (a gift from Dr. Eric Shusta) for protein secretion and purification.  
Cells were grown in 500 mL of SD-CAA plus tryptophan media at 30 oC, 250 rpm for 3 days, 
pelleted, and re-suspended in 500 mL of SG-CAA plus tryptophan with 0.1% bovine serum 
albumin (Sigma-Aldrich) at 20 oC, 250 rpm for 3 days to induce and secrete the scFvs. The cells 
were pelleted, and supernatant containing scFv was collected and filtered using bottle-top filter 
(Corning, PES membrane, 0.22 µm) to remove the yeast cells and cell lysate. The scFv 
supernatant was firstly concentrated to 50 mL by ultrafiltration using a selective permeable 
membrane (Millipore Sigma, 10 kDa) under nitrogen pressure. The concentrated supernatant was 
then dialyzed to exchange buffer in 5 L of phosphate-buffered saline (0.01 M sodium phosphate, 
0.15 M NaCl, pH 8.0) at 4 oC overnight. The dialyzed scFvs solution was purified as described 
previously (38), using the SuperFlow Ni-NTA beads (Qiagen). The purified scFvs were resolved 
using SDS-PAGE in tris-glycine running buffer (14.4 g/L glycine, 1 g/L SDS, 3.03 g/L Tris base) 
with 12 % Bis-Tris gels. SeeBlue® pre-stained protein standard (Thermo Fisher Scientific) was 
used to determine the molecular weights.  
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3.2.5 Fluorescent tagging of purified pT231 scFvs 
The scFv elution fractions were pooled and concentrated using a centrifugal filter unit (Millipore 
Sigma, Amicon Ultra, 10 kDa MWCO).  The concentrated scFvs were diluted to 3 mg/mL in 0.1 
M sodium bicarbonate buffer at pH 8.3. The amine-reactive dye Alexa Fluor 594 NHS ester 
(Thermo Fisher Scientific) was prepared in dimethylformamide (DMF) at 10 mg/mL 
immediately before use. 35 µg of Alexa Fluor 594 NHS ester from the stock solution was added 
to 100 µg of purified scFv. The reaction mixture was incubated for 1 hour at room temperature in 
the dark. Unreacted dye was removed using the Zeba desalting columns (Thermo Fisher 
Scientific, 7 kDa MWCO), and the concentrations of modified scFvs were determined using a 
Bradford assay (Thermo Fisher Scientific). 
3.2.6 Immunocytochemistry in HEK 293 cells 
The HEK 293 cells were transfected with pRK5-EGFP-Tau (Addgene 46904), which contained 
human tau (MAPT 0N4R) fused to EGFP at the N-terminus. Cells were rinsed once with 0.5 mL 
of ice-cold PBSCM buffer (0.15 M NaCl, 1.9 mM NaH2PO4, 8.1 mM Na2HPO4, 1 mM CaCl2, 
0.5 mM Mg2SO4, pH 7.4), fixed in 4% paraformaldehyde (Sigma) in PBSCM at room 
temperature for 15 min, and then permeabilized using 0.1% Triton X-100 (Acros Organics) in 
PBSCM at room temperature for 15 min. After washing three times with PBSCM, the cells 
incubated with 0.1 µM of Alexa Fluor 594 conjugated scFv in 0.5 mL of PBSCM with 40% goat 
serum (PBSG) at 4 oC overnight in the dark. The cells were washed three times with ice cold 0.5 
mL PBSCM, stained with 0.3 µM of DAPI (Thermo Fisher Scientific) at room temperature for 5 
min, washed once with 0.5 mL of ice-cold PBSCM. The cells were imaged using a Nikon A1R 
confocal microscope (UConn Center for Open Research Resources and Equipment).  
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3.2.7 Immunohistochemistry in brain tissue sections 
All mouse (n=3 PS19, 3 wild-type C57BL6/J, and 3 tau knock-out) and human (n=2 AD cases 
and n=2 aged control) tissues were sectioned at 30 µm stained as free floating sections using 
Netwell baskets (VWR Cat#29442-132) in 12-well Falcon plates (Cat#353043). Extracted mouse 
tissues were flash frozen on dry ice, sectioned onto slides (Millenia 2.0 Adhesion Slides Catalog 
# 318), and fixed in cold 4% PFA for 3 minutes prior to staining. Human tissues were fixed and 
stored in PLP until sectioned using a Leica VT1200S vibratome. To quench lipofuscin 
autofluorescence, human tissue sections were photobleached under a 1500 lumen white LED 
bulb for 72 hours at 4°C while suspended in PBS with no lid or covering (39). Following mouse 
tissue fixation and human tissue bleaching, all sections were then washed three times in PBS for 
30 seconds per wash followed by a 5-minute incubation in detergent media (TBS with 0.25% 
Triton-X). Tissue was then incubated for 30 minutes in citrate-based antigen unmasking solution 
(Vector Cat#H-3300) at 95°C. Tissue was blocked with gentle rotating for 2 hours in detergent 
media with 5% donkey serum (Sigma-Aldrich D9663-10mL). After blocking, free floating 
human tissue sections were moved into separate wells of a 24-well plate with 300 µL of the 
appropriate scFv dilution and no basket; mouse tissue was stained directly on the slides with 200 
µL of the appropriate scFv dilution. Tissues were incubated with the scFvs for 3 hours at room 
temperature with gentle rotation.  
Following scFv incubation, tissue sections were incubated with 1 µg/mL of DAPI in the dark for 
5 minutes at room temperature. Tissues were then washed four times in PBS for 5 minutes each 
and carefully placed on Millenia 2.0 slides using a histology brush if free floating (Fisher 
Scientific Cat#NC0344756). Excess water was allowed to evaporate for 15 minutes, then each 
slide was mounted with 100uL of Prolong Gold Antifade Reagent (Thermo Fisher Cat#P36930) 
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and a 1 mm cover slip. Imaging was done using a Zeiss LSM 710 confocal microscope, ensuring 
equal parameters for digital gain (790), pinhole (30 um), and laser power (4.4%) for all images. 
Following imaging, images were processed using the Fiji distribution of ImageJ.  The magic 
wand tool was used to select individual tangles as a region of interest (ROI) which was then 
measured for average fluorescence intensity 
 
 Results 
3.3.1 Yeast surface display of a phospho-tau scFv 
To test our hypothesis, we first developed an assay to quantify antibody specificity using yeast 
surface display (Figure 3.1). Synthetic peptides that represent the exact target epitope, as well as 
other potentially cross-reacting species were labeled for detection. Since yeast surface display 
allows surface expression of 40,000-50,000 scFvs per cell (35,40), we anticipated that binding of 
multiple structurally-related epitopes displayed on yeast could be quantified using multicolor 
flow cytometry (Figure 3.1). To demonstrate this concept, we used the previously identified 
high-specificity anti-phospho-tau antibody which targets pT231 (27). We cloned the antibody as 
a VL-VH single-chain variable region fragment (pT231 scFv), fused to the N-terminus of the 
yeast cell wall protein Aga2p (Figure 3.1).  
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Figure 3.1 Schematic representation of antibody specificity quantification using yeast surface display 
Individual peptide epitope binding to single chain variable region fragments displayed on yeast can be 
quantified. By labeling multiple peptides with distinct tags, competitive binding of potentially cross-reacting 
epitopes, such as a phosphopeptide and non-phosphopeptide (peptide mix indicated by a dotted box) can be 
quantified using multicolor flow cytometry. 
 
3.3.2 Chemical labeling of peptides to generate distinctively labeled epitopes 
To detect the interaction between pT231 scFv and the target phosphoepitope, a synthetic 
phosphopeptide (Pphos, KKVAVVRpTPPKpSPSSAKC) was labeled with Alexa 488 at the C-
terminal cysteine using Alexa Fluor 488 C5 maleimide. The resulting peptide was purified using 
high-performance liquid chromatography (HPLC), and the label was validated using mass 
spectrometry (Figure 3.2a). To quantify the specificity of the scFv to structurally similar 
epitopes, including the non-phosphoepitope and a phosphoepitope with scrambled amino acid 
sequence, we labeled peptides representing the non-phosphoepitope (Pnonphos, 
KKVAVVRTPPKSPSSAKC) and a scrambled phosphoepitope (Pscram, 
KAVpSASVPVSRKpTKPPKC) with biotin at the C-terminal cysteine using maleimide-PEG11-
biotin (Figure 3.2, data not shown). To enable measurement of binding curve, we also generated 
a phosphopeptide labeled with a second tag, biotin (Figure 3.2b). 
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Figure 3.2. Modified peptides purification and confirmation 
a, conjugation of Alexa Fluor 488 C5 maleimide to cysteine-Pphos and HPLC purification. HPLC elution 
profiles of free cysteine-Pphos (top), free Alexa Fluor 488 C5 maleimide (second), and conjugation reaction of 
the cysteine-Pphos to Alexa Fluor 488 C5 maleimide (bottom). A good separation between the Pphos-
A488conjugate and other reactants facilitates purification. b, mass spectra showing Pphos-b and Pnonphos-b 
conjugate with no free cysteine-peptide. 
 
3.3.3 Verification of binding activity of yeast displayed pT231 scFv 
The scFv expression on the yeast cell surface and binding to the phosphoepitope were confirmed 
using confocal microscopy (Figure 3.3a), using Streptavidin-R-phycoerythrin (SA-PE) as a 
detection reagent. The affinity (dissociation constant Kd) of the yeast displayed pT231 scFv, as 
determined by titrating the biotinylated phosphopeptide (Pphos-b) was 2.2 ± 0.4 nM (Figure 
3.3b, mean ± standard deviation), which is lower than the monovalent affinity for the full-length 
IgG (Kd = 0.35 nM) generated using the same variable regions (27). Even though scFv constructs 
are highly advantageous for imaging (41) and delivery (42-44), a 5 to 15-fold reduction in 
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affinity upon conversion of IgG to scFv had been reported (42,45), potentially due to higher 
stability and functional concentration of full IgGs.  
 
Figure 3.3 Binding activity of yeast displayed pT231 scFv 
a, confocal microscope images of yeast displayed pT231 scFv and an isotype-matched control scFv. scFv 
expression shown in red was detected using a mouse anti-FLAG antibody to assess full-length scFv expression. 
Cognate phosphopeptide (Pphos) binding is indicated in green. Scale bars, 5 µm. b, affinity measurement of 
yeast displayed pT231 scFv. The yeast cells were incubated with serial dilution of Pphos. Error bars indicate 
standard deviation from three independent experiments. 
 
To confirm that the yeast displayed scFv was properly folded, we generated alanine point 
mutations in the CDR residues that interacted with the phosphoepitope (Figure 3.4), according 
to the published x-ray structure of the antibody-phosphopeptide complex (27). Alanine point 
mutations in all phosphoepitope interacting CDRs (single alanine substitutions in either CDR-H2, 
CDR-H3, CDR-L1, CDR-L2, or CDR-L3) substantially reduced phosphopeptide binding 
(Figure 3.4), indicating that CDR residues were correctly presented in the yeast displaying scFv.  
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Figure 3.4 Assessment of CDR mutations on phosphopeptide binding of yeast displayed pT231 scFv 
Alanine point mutations were introduced to scFv residues that directly interact with the phosphopeptide, 
according to the pT231 Fab-phosphopeptide crystal structure (PDB entry 4GLR). Yeast displayed wild-type 
pT231 scFv and alanine point mutants at indicated amino acid positions were incubated with Pphos-b at 1 µM. 
Control scFv indicates an isotype-matched random scFv. Amino acid numbering and CDRs are defined 
according to Kabat numbering scheme. Error bars indicate standard deviation from three independent 
experiments. Dunnett's multiple comparisons test, * P ≤ 0.05, **** P ≤ 0.0001, otherwise, P > 0.05. 
 
3.3.4 Assessment of antibody phospho-specificity using yeast surface display 
Having verified the binding activity of the pT231 scFv, we quantified the specificity of the scFv 
to structurally similar epitopes, including the non-phosphoepitope and a phosphoepitope with 
scrambled amino acid sequence. When we assessed the binding of pT231 to the phosphopeptide 
labeled with Alexa 488 (Pphos-A488) using flow cytometry, we found that the signal intensity of 
scFv-phosphopeptide was lower, compared to the signal obtained from Pphos-b (data not shown). 
Such a difference could be attributed to the fact that the brightness of R-phycoerythrin (molar 
absorption coefficient ´ quantum yield = 19.6 ´ 105 M-1cm-1 ´ 0.82 = 16.1 ´ 105 M-1cm-1) (46) is 
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24-fold higher than that of Alexa 488 (0.73 ´ 105 M-1cm-1 ´ 0.92 = 0.67 ´ 105 M-1cm-1, 
manufacturer specifications). Therefore, we amplified the signal from Alexa 488, using an anti-
Alexa 488 antibody (rabbit polyclonal) followed by an anti-rabbit IgG conjugated with Alexa 
488, which resulted in 10-fold increase in the scFv-Pphos-A488 signal (data not shown). When 
yeast cells displaying the pT231 scFv were incubated with an equimolar mixture of Pphos-b and 
Pphos-A488 (both at 0.5  µM), signals from both labels were detected using flow cytometry 
(Figure 3.5), as anticipated in the multi-color labeling scheme (Figure 3.1). To assess the 
specificity, yeast cells displaying pT231 scFv were incubated with a mixture of either Pphos-
A488 and Pnonphos-b (both at 0.5  µM) or Pphos-A488 and Pscram-b (both at 0.5  µM). In these 
experiments, the yeast cells showed labeling almost exclusively by the target phosphopeptide 
(Pphos-A488), and no detectable binding to the non-phosphopeptide (Pnonphos-b) or scrambled 
phosphopeptide (Pscram-b) (Figure 3.5). These results confirmed the previous report of high 
specificity of the pT231 antibody (27), and demonstrated the effectiveness of our specificity 
quantification assay. 
 
Figure 3.5 Assessment of the specificity of yeast displayed pT231 scFv 
Flow cytometry dot plots for yeast displayed WT pT231 scFv (top row) or an isotype-matched control scFv 
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(bottom row). The first column shows data for scFv expression and biotinylated phosphopeptide (Pphos-b) 
binding. In the following columns, yeast cells were incubated with a mixture of either Pnonphos-b and Pphos-
A488 (second column), or Pscram-b and Pphos-A488, or Pphos-b and Pphos-A488, all at 0.5 µM. 
 
3.3.5 Directed evolution of pT231 scFv for improved affinity 
We performed directed evolution of the pT231 scFv by applying selection pressure to enhance 
the affinity (Figure 3.6a). We generated a random mutation library of the pT231 scFv using 
error-prone PCR (47) followed by electroporation in yeast (48), yielding approximately 3  ´ 107 
transformants displaying the scFv variants. The scFv library was subjected to three rounds of 
fluorescence-activated cell sorting (FACS) (Figure 3.6a). After round 1 and 2, the sorted scFv 
sequences were further diversified using DNA shuffling followed by random mutagenesis 
(Figure 3.6a). Throughout the FACS process, selection pressure for higher affinity was applied 
by incubating yeast cells displaying pT231 mutants with progressively lower concentration of 
Pphos-b (Figure 3.6a) followed by incubation with 1 µM of unlabeled phosphopeptide (Pphos) 
for dissociation (49), and sorting for high Pphos-b binding vs. scFv expression (using anti-c-Myc 
antibody) (Figure 3.6b). After three rounds of FACS, a population of high Pphos-b was enriched 
(Figure 3.6c).  
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Figure 3.6 Directed evolution of yeast displayed pT231 scFv variants with improved affinity 
a, flow chart for the directed evolution process. High-affinity variants were sorted using FACS. b, flow 
cytometry dot plot with a sorting gate used for screening cells with scFv expression and high Pphos-b binding. 
c, Dot plots comparing yeast displaying WT pT231 scFv (left) and a yeast pool resulting from three rounds of 
sorting and mutagenesis (right) were labeled for scFv expression and Pphos-A488 binding. 
 
We sequenced individual clones from this pool and identified 27 unique scFv mutant sequences 
(Figure 3.7). Even though all 27 clones had distinct sequences with mutations throughout the 
scFv sequence, several high occurrence mutations were found (Figure 3.7).  
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Figure 3.7 Amino acid sequence of individual mutants isolated from the screen for improved affinity 
The sequences in the boxes indicate CDRs. High occurrence mutations are indicated in bold. Kabat numbering 
is indicated at the top. 
 
The majority of frequent mutations (residues with occurrence labeled in bold in Figure 3.7) were 
found in or near the CDRs (Kabat numbering): VLW50L and VLS56C (L2), VLA95T, 
VHG100HD (or S), VHD101G, and VHA102T (H3) (Figure 3.8). Mutations VLD57G, VHG74C, 
and VHA93V were in the framework regions (Figure 3.8).  
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Figure 3.8 High occurrence mutations identified from the screen mapped on WT pT231 scFv structure 
Heavy chain is shown in green and light chain in purple. Position of high occurrence mutations are indicated in 
red, and labeled with the wild-type amino acid. Boxed amino acids indicate those mutated in the scFv 3.24. 
The structure was generated using CCP4MG, based on protein data bank (PDB) entry 4GLR. 
 
3.3.6 Characterization of affinity and specificity of scFv mutants 
To assess the effectiveness of the directed evolution, we characterized the clones isolated after 
three rounds of sorting for their affinity and specificity. For these analyses, we chose the first 14 
unique clones identified from sequencing (clones 3.1 to 3.14, Figure 3.7). To rapidly compare 
the affinity to that of the WT pT231 scFv, we incubated yeast cells displaying mutant scFvs with 
2 nM of Pphos-b, which was near the Kd of the WT pT231 scFv. At this peptide concentration, 7 
out of 14 clones showed significantly higher binding (normalized to the scFv expression level) 
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compared to that of the WT scFv (Figure 3.9a, P < 0.05, Dunnett’s multiple comparisons test). 
Based on the binding/expression level, we chose scFv mutant 3.05 (containing 6 mutations, 
Figure 3.7) and measured its affinity by displaying it on yeast and generating a titration curve 
for the Pphos-b binding (Figure 3.9b). scFv 3.05 showed a 21-fold improvement in affinity over 
that of the WT pT231 scFv, reaching picomolar monovalent binding affinity (Kd = 92 ± 1 pM) 
(Figure 3.9b). To characterize the phospho-specificity of the 14 mutant clones, we first 
measured the individual binding to Pnonphos-b and Pscram-b of the 14 clones (Figure 3.9c, d). 
We found that of the 14 clones, 6 showed significant binding to the Pnonphos-b (Figure 3.9c, P 
< 0.01, Dunnett’s multiple comparisons test), while none of the clones showed detectable 
binding to the Pscram-b (Figure 3.9d). When we assessed the specificity of the high-affinity 
scFv 3.05 using competitive binding between Pphos-A488 and Pnonphos-b, significant binding 
to Pnonphos-b was detected (data not shown). Taken together, these results suggested that some 
of the clones gained affinity by stabilizing the interaction to the target peptide sequence, while 
none of the clones gained affinity to the phosphate group alone to cause cross-reactivity towards 
Pscram-b. Conversely, the fact that some of the clones did not show significant binding to the 
Pnonphos-b (Figure 3.9c) suggested that improving affinity did not necessarily lead to enhanced 
cross-reactivity towards the non-phosphorylated epitope. In order to identify an optimal clone 
with improved affinity and high specificity, we selected additional clones based on the sequence 
homology and occurrence of mutations (Figure 3.7), and assessed their binding to Pphos-b, 
Pnonphos-b, and Pscram-b. From this characterization, we identified scFv 3.24 (containing 5 
mutations) that showed 11-fold of improvement in binding affinity over the WT pT231 (Figure 
3.9e, Kd = 160 ± 50 pM) and no significant change in binding to Pnonphos-b compared to that of 
wild-type pT231 (Figure 3.9f). These results indicate that in phospho-specific antibodies, 
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applying selection pressure towards improved affinity does result in cross-reactivity in a 
significant fraction of clones. Therefore, high-affinity clones need to be checked for phospho-
specificity in order to improve the binding affinity through directed evolution. 
 
Figure 3.9 Characterization of affinity and specificity of individual scFvs 
a, binding intensity normalized to the expression level of yeast displayed WT pT231 scFv and mutants to 
Pphos-b at 2 nM. The right most sample was the WT pT231 scFv incubated with Pphos-b at 1 µM, as a 
positive control. b, Affinity titration for yeast-displayed scFv 3.05. Binding intensity of yeast displayed WT 
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pT231 scFv and mutants to Pnonphos-b at 1 µM in c, and Pscram-b at 1 µM in d, respectively. e, affinity 
titration for yeast-displayed scFv 3.24. f, Binding intensity normalized to the expression level of yeast 
displayed WT pT231 scFv and mutants to Pnonphos-b at 1 µM. Error bars indicate standard deviation from 
three independent experiments. Statistics for panels (a, c, d, and f): Dunnett's multiple comparisons test, *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, otherwise, P > 0.05. 
 
3.3.7 Cell and tissue section labeling using purified scFvs 
High affinity and specificity reagents are expected to enable sensitive detection of tau 
phosphorylation in complex samples. We tested the performance of the scFvs in 
immunocytochemistry and immunohistochemistry experiments. In order to perform the labeling 
experiments, we cloned the wild-type scFv and mutant 3.24 into a vector containing a synthetic 
secretion signal (38) to secrete them using yeast S. cerevisiae. The secreted scFvs were purified 
using a hexa-histidine motif at the C-terminus. When we resolved the purified scFvs using SDS-
PAGE followed by Coomassie staining, the gel loaded with purified scFvs showed a single 
protein band with a molecular weight of 28 kDa, which is typical for scFvs (50), with ~92% 
purity as quantified by densitometry of the gel (data not shown). To enable direct imaging of the 
scFvs without the use of secondary reagents, the purified scFvs were fluorescently labeled with 
Alexa 594 through modification of lysine residues (NHS-Alexa Fluor 594) and purified. In order 
to assess the specificity, the fluorescent scFvs were used to label human embryonic kidney cells 
(HEK293FT) transiently expressing human tau (microtubule-associated protein tau (MAPT) 
0N4R) as a GFP fusion (EGFP-tau) (51). When high concentrations (100 nM) of the WT pT231 
scFv or scFv 3.24 were used for staining, clear scFv signal was detected in HEK293FT cells 
expressing wild-type tau (Figure 3.10, top row) but not to the same cells treated with 𝜆 
phosphatase (Figure 3.10, second row). These results indicate that the binding of wild-type 
pT231 scFv and mutant 3.24 requires phosphorylation of tau, and as reported previously, the tau 
expressed in HEK293 cells is phosphorylated (52,53). In order to further assess the specificity of 
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the scFvs, we generated point mutants of human tau at the target phosphorylation site (T231) 
either incapable of phosphorylation (T231A) or pseudophosphorylated (T231E). In HEK293FT 
cells expressing EGFP-tau T231A, both the wild-type pT231 scFv and mutant 3.24 showed no 
detectable binding (Figure 3.10, third row), while in the same cells expressing EGFP-tau T231E, 
both scFvs showed clear binding (Figure 3.10, bottom row). These results indicate that the scFv 
binding requires tau phosphorylation at T231.  
 
Figure 3.10 Confocal microscopy images of HEK293FT cell labeled using purified pT231 scFvs 
Purified fluorescently labeled WT pT231 scFv and mutant 3.24 binding to HEK293FT cells expressing WT tau 
(top row), WT tau treated with lambda phosphatase (second row), tau T231A (third row), and tau T231E 
(bottom row). All human tau constructs were fused to EGFP at the N-terminus (EGFP-tau). The first column 
shows DAPI staining in blue. The second column shows tau expression in green. The third column shows scFv 
binding in red. Scale bars, 50 µm. 
 
When we compared the labeling of WT and scFv 3.24 at lower concentrations, scFv 3.24 showed 
significantly higher binding signal above background compared to that of WT at scFv 
concentrations ranging from 80 pM to 50 nM (Figure 3.11, P < 0.05, student’s t-test).  
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Figure 3.11 Quantification of cell labeling fluorescence intensity using purified pT231 scFvs 
Fluorescence intensity of WT pT231 scFv and mutant 3.24 binding to HEK293FT cells expressing WT tau 
was measured at scFv concentrations from 16 pM to 50 nM. Error bars indicate standard deviation from three 
independent experiments. Statistics: Student’s t-test, *P ≤ 0.05. 
 
We proceeded to test the fluorescently labeled scFvs in the staining of tissue sections from both 
PS19 mouse tissue slices and human AD tissue slices; PS19 mice expressed the aggregation-
prone mutant P301S of human tau (1N4R) under the mouse prion protein (Prnp) promoter (54). 
In brain slices of 8-month old PS19 mice, wild-type pT231 scFv and mutant 3.24 demonstrated 
staining patterns characteristic of neurofibrillary tangles (Figure 3.12a), suggesting specific 
labeling of tau. This staining was dose-dependent for both scFvs (Figure 3.12b). Neither scFv 
showed detectable staining in either tau knock-out or WT C57Bl/6 mice (Figure 3.12c). Staining 
of human AD tissue also revealed characteristic tangle staining (Figure 3.12d) with no 
detectable staining in aged control brain tissues. However, in the human tissues the mutant scFv 
3.24 showed significantly higher signal than the WT scFv at the 50 nM working concentration 
(Figure 3.12e), suggesting higher affinity and more robust staining for the mutant scFv. These 
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results further demonstrate that the high-affinity antibody generated in this study has 
exceptionally high specificity for phospho-tau. 
 
Figure 3.12 Tissue labeling using purified pT231 scFvs 
a, immunohistochemistry using the scFvs on brain slices of 8-month old mice expressing P301S mutant tau 
indicates that both scFvs robustly identify neurofibrillary tangles in tissue. Each scFv was used at 50 nM and 
10 nM to identify optimal staining concentrations and show a dose response for staining intensity, quantified in 
b. tau is shown in red with nuclei stained using DAPI in blue. The 10nM concentrations showed significant 
reduction in staining intensity for both the WT and 3.24 scFv (P ≤ 0.0001 by one-way ANOVA with P ≤ 
0.0001 between the 50 nM and 10 nM working concentrations of each scFv using Tukey’s multiple 
comparisons test). There were no statistical differences between the WT and 3.24 scFv at either concentration. 
c, neither scFv stained WT or tau knockout mouse tissue at the 50 nM working concentration, indicating no off 
target staining or background fluorescence. d, immunohistochemistry of human AD and aged control tissues 
also indicate that both scFvs stain phospho-tau tangles in disease (scFv concentration = 50 nM). However, in 
the human tissue the high affinity scFv 3.24 shows a significant increase in staining intensity compared to the 
WT scFv, which is quantified in e (P ≤ 0.0001 using a two-sample t-test assuming unequal variances). 
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 Discussion 
In this study, we applied directed evolution to enhance the affinity of a phospho-specific 
antibody, and quantified the impact of in vitro affinity maturation on specificity. High-affinity 
antibody fragments with dissociation constants reaching picomolar range were successfully 
generated. Based on the crystal structure of the WT pT231 antibody bound to the 
phosphopeptide (27), only one mutation occurred in a residue that directly contacts the 
phosphoepitope (Figure 3.8, VLW50L). Five out of 9 high occurrence mutations were located 
near the direct contact sites (VLS56C, VLA95T, VHG100HD (or S), VHD101G, and VHA102T). 
The pattern of mutations occurring in amino acid positions near, but not at the direct contact site 
has been frequently observed in high affinity antibody variants (55,56). Such mutations may 
contribute to enhanced affinity through preorganization and rigidification of the paratope (57-59). 
Mutations VHG100HD, VHD101G, and VHA102T are also located at the VH-VL interface, 
suggesting that stability of interaction between the two domains may contribute to affinity 
improvement. Interestingly, high occurrence mutations found in the optimal variant 3.24 
(VLD57G, VHG74C, and VHA93V) were exclusively located in the framework region. This 
suggests that this variant may have gained affinity through optimization of structural plasticity 
(60,61). Further investigation on the impact of individual mutations on affinity and specificity 
may provide new insights on designing PTM-specific antibodies. 
High-affinity reagents would be highly advantageous in detecting PTMs from complex samples. 
Our results show that the high affinity variant scFv generated significantly higher signal 
compared to that of the wild-type scFv in detecting tau from human tissue, but not in mouse 
tissue. The discrepancy in staining intensities may be explained by differences in the expression 
level of human tau and level of phosphorylation. In the transgenic mice PS19, the expression of 
  53 
human tau P301S is driven by the prion protein promoter, which is strongly induced in neuronal 
cells (62), leading to 3-5 fold higher levels of tau expression than endogenous levels (54). 
Moreover, in PS19 mice, the solubility of tau decreases by 3 months of age, and becomes 
hyperphosphorylated (54,63). Therefore, the level of insoluble aggregates of phosphorylated tau 
in the mouse tissue may be significantly higher than in human AD patient tissue. Additionally, in 
the mouse tissue, the labeling intensity was significantly diminished at a scFv concentration of 
10 nM, suggesting a possibility for mass transfer limitation of the labeling reagent. Very slow or 
limited antibody penetration has been reported for fixed samples (64). This shows the need for 
high antibody concentrations in labeling fixed tissue, and highlights the importance of antibody 
specificity. 
While the scFv identified in this study can be converted to full-length IgGs, the scFv construct 
provides unique advantages for detecting tau due to its small size. Compared to full-length IgGs 
(150 kD), scFvs are approximately one-sixth in molecular weight (25 kD). This has led to 
significant enhancement in processes that rely on diffusion, such as tissue penetration. For 
example, when the blood-brain barrier was transiently opened through focused ultrasound, scFvs 
showed 5- to 57-fold higher uptake into the central nervous system compared to IgGs (44). In a 
mouse model of tauopathy, intravenously injected scFvs were detected in the brain tissue in 
significantly higher levels compared to that of IgGs (41). Moreover, scFv constructs enable 
wider modes of delivery since they are encoded by a short single gene that can be packaged in 
viruses. For example, intracerebroventricular injection of adeno-associated viruses carrying an 
anti-tau scFv resulted in reduced tau accumulation in a mouse model of tauopathy (43). Finally, 
we demonstrated cell and tissue staining using scFvs directly labeled with a fluorophore. These 
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reagents have the potential to enable sub-diffraction limit imaging of phospho-tau due to greatly 
reduced linkage error, which limit image resolution (65). 
Phosphorylation of tau at T231 is a widely recognized modification for its association with AD. 
In vitro and in cultured cells, pT231 decreases the ability of tau to bind and stabilize 
microtubules (66,67). pT231 seems to occur early in AD progression and precedes paired helical 
filament (PHF) formation (68). pT231 was found in the cerebrospinal fluid (CSF) of patients 
with mild cognitive impairments who eventually developed AD (69). In addition, levels of 
pT231 in the CSF were correlated with rates of hippocampal atrophy in AD patients (70). An 
immunoassay of pT231 in the CSF demonstrated a 85% sensitivity (detection in 23 out of 27 AD 
samples) and a 97% specificity (detection in 1 out of 31 non-AD samples) in AD brain extracts 
(71). The high affinity and specificity pT231 tau antibody developed in this study is expected to 
enhance the sensitivity and enable earlier detection of pT231. 
A major finding of this study is that in vitro affinity maturation of the phospho-specific antibody 
led to an increase in unwanted cross-reactivity towards the non-phosphorylated target sequence 
in a majority of high-affinity variants. Considering the fact that the area of interaction available 
from a modified amino acid is limited, stabilization of interaction with the nearby amino acid 
sequence may be a common phenomenon in high-affinity PTM-specific antibodies. In a recent 
study, monoclonal antibodies generated in guinea pig against pT18 of p53 showed picomolar 
affinity (Kd = 0.20 nM) but also significant binding to the non-phosphorylated p53 (Kd = 130 nM) 
(72). If such antibody is used at concentration ranges commonly used for cell or tissue staining 
(10 - 50 nM), false positive signal from cross reactivity towards the non-modified target may be 
detected. This illustrates an important point that antibody specificity is a function of antibody 
concentration. Therefore, existing PTM-specific antibodies should be validated for their 
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specificity under varying concentrations. We suggest setting an upper concentration limit for 
each PTM-specific antibody to prevent false positive detection. Until now, efforts to validate and 
enhance specificity has been rarely made. Non-specific antibodies would be a major factor in 
irreproducibility in biological experiments. Ongoing efforts to standardize ways to quantify and 
document specificity of binding reagents (73) need to consider these aspects of antibody 
specificity. 
We introduced an approach using yeast surface display to quantify the specificity of PTM-
targeting antibodies. This enabled us to find that even among antibody variants selected only for 
improved affinity, a fraction of clones maintained high specificity. This specificity quantification 
approach may be widely adopted due to the general applicability of yeast surface display and its 
compatibility with flow cytometry. We demonstrated the use of this approach for a phospho-
specific antibody, but it is readily applicable to other PTM-specific antibodies. In principle, this 
approach would be suitable for assessing the specificity of affinity reagents in general. The 
identified high-affinity variant showed exceptional specificity, as validated by cell and tissue 
staining experiments. Due to the compatibility with FACS, this approach has potential to enable 
directed evolution of antibody specificity. In particular, it would be useful in engineering the 
specificity of antibodies with known cross-reactivity. For example, a recent study showed that a 
significant fraction of commercially available PTM-specific tau antibodies has cross reactivity 
(34). Directed evolution may be applied to reduce the cross-reactivity of these antibodies. 
 
 Conclusion 
In this study, we introduced an approach using yeast surface display to quantify the specificity of 
phospho-specific antibodies. We demonstrated the use of this approach for a phospho-specific 
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antibody, but it is readily applicable to other PTM-specific antibodies. In principle, this approach 
would be suitable for assessing the specificity of affinity reagents in general. We also developed 
a screening assay based on it to generate PTM-specific antibodies with improved affinity and 
high specificity. We demonstrated that improving PTM- specific antibody affinity through 
directed evolution results in cross-reactivity to the non-modified target sequence, there’s a trade-
off between affinity and specificity in PTM antibodies. However, quantifying specificity leads to 
identification of a variant with high affinity and specificity. 
The results from this study demonstrate that in vitro affinity maturation is a viable option for 
improving the affinity of PTM-specific antibodies. In this process, it is essential to quantify the 
specificity, particularly to the non-modified target sequence. By quantifying the specificity, it is 
possible to apply selection pressures for improved affinity and specificity simultaneously. 
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 Introduction 
Site-specific phosphorylation of the microtubule-associated protein tau is a well-defined 
molecular signature linked to normal tau function as well as pathology in neurodegeneration. 
Antibodies binding to phosphorylated tau (phospho-tau) are extensively used in research and 
being adopted in clinical diagnosis (1-6). According to antibody databases (Antibodypedia and 
Alzforum), thousands of anti-tau antibodies are currently available, including >180 unique 
phospho-tau antibodies. However, few validation data have been published (7-9), which 
indicated an alarming degree of non-specific binding frequently observed in phospho-tau 
antibodies. To prevent waste of resource and irreproducibility of results, a standard measure of 
specificity, equivalent to dissociation constants (Kd) for measuring affinity, is urgently needed. 
Ideally, this parameter should enable users to compare the specificity, identify the source of non-
specificity, and clearly understand what is measured. 
Existing specificity characterization methods relied on immunoblotting approaches using either 
synthetic peptides, cell lysates or extracted paired helical filament (PHF) tau (7-9). Synthetic 
peptides allow binding measurement to exactly defined phosphorylation sites, but is prohibitively 
costly to cover all phospho-sites across the full-length tau. Cell lysates allow detection of non-
specific binding to non-tau proteins (for example by using cell lysates from a tau knockout 
mouse) (7), but cannot measure cross-reactivity to non-modified tau or other phosphorylation 
sites. Extracted PHF-tau from AD brain homogenates allows characterizing antibodies that do 
not recognize normal human adult tau and measuring the cross-reactivity to nonphospho-tau by 
treatment with phosphatase, but cannot capture the phospho-site specificity (9). Steinhilb and 
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colleagues have generated transgenic flies expressing tau with alanine point mutations at several 
serine-proline and threonine-proline motifs of human tau (10). In this study, they used fly head 
extracts from these transgenic lines to perform western blotting using phospho-tau antibodies. In 
principle, this approach may be applied for validating phospho-tau antibodies. However, all of 
these approaches are not ideal for quantitative measurement due to frequent signal saturation in 
immunoblotting experiments (11). To fill this critical need, we introduce a parameter termed Φ 
(12) that quantifies specificity of phospho-tau antibodies and establish a generalizable, robust 
assay to measure it.  
The approach leverages flow cytometry for quantitative, multi-dimensional analysis of small 
changes in antibody binding to different cell populations. In a typical immunodetection 
experiment, signal from specific and non-specific binding cannot be distinguished. We sought to 
enable this distinction within a single sample, by generating two populations of cells with 
distinct fluorescence reporters. In one population of cells, the target protein (i.e., tau) is 
expressed as a fusion to the enhanced green fluorescent protein (EGFP). In another population, 
tau containing a site-specific alanine mutation is expressed as a fusion to a near infra-red 
fluorescent protein (iRFP). The two populations of cells are mixed, and labeled with a phospho-
specific antibody. For a phospho-site specific antibody, any binding to iRFP-positive cells is 
non-specific binding, enabling the measurement of the fraction of non-specific signal among all 
antibody binding signals. In order to ensure the measurement of cross-reactivity to non-
phosphorylated tau, the experiment is repeated by replacing alanine mutant expressing cells with 
tau expressing cells (iRFP fused to wild-type tau) treated with the lambda protein phosphatase 
(λPP). Analogous to the alanine mutation assay, binding to iRFP-positive cells is identified as 
non-specific signal. Based on these measurements, the fraction of non-specific signal is 
  64 
calculated, which is subtracted from 1 to obtain Φ. Therefore, Φ indicates the fraction of specific 
signal.  
Using this measurement, we measured the specificity Φ  of 7 commonly used phospho-tau 
antibodies (AT270, AT8, AT100, AT180, PHF-6, TG-3, and PHF-1), in addition to others. Our 
results show that 5 antibodies (AT8, AT180, PHF-6, TG-3, and PHF-1) have Φ values near 1, 
indicating nearly perfect specificity. Antibodies AT270, AT100 showed weak but detectable 
non-specific binding to non-tau proteins in cells, with lower Φ  values. This resulted in 
background fluorescence in flow cytometry and immunocytochemistry experiments. The non-
specific binding also resulted in false positive detection in western blots, evidenced by additional 
bands appearing in cell lysates that do not contain human tau. To our knowledge, this is the first 
quantitative measurement of antibody specificity that enables specificity comparison with 
information on the source of non-specificity. 
 
 Materials and Methods 
4.2.1 Cloning of recombinant constructs of tau and mutant tau 
The following plasmids were obtained from Addgene: a mammalian expression vector pRK5 
encoding EGFP tagged wild-type (13) human tau (pRK5-EGFP-tau, # 46904, RRID: 
Addgene_46904), which contains four C-terminal repeat regions and lacks the N-terminal 
sequences (0N4R), a plasmid encoding iRFP (piRFP670-N1, # 44457, RRID: Addgene_45457), 
and a mammalian expression vector pcDNA3 encoding hemagglutinin tagged constitutively 
active glycogen synthase kinase-3b (GSK-3β) (S9A) (pcDNA3-GSK3b, # 14754, RRID: 
Addgene_14754). The EGFP in pRK5 vector was first replaced by iRFP to construct an iRFP 
tagged WT tau by golden gate assembly (pRK5-iRFP-tau) (14). This assembly was performed 
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using a Type IIs restriction enzyme BsaI (New England Biolabs # R3535) and T4 DNA ligase 
(New England Biolabs # M0202) (see Table 4.1 for primers used). Seven alanine mutant 
variants were generated in iRFP tagged tau to preclude phosphorylation. Alanine mutations were 
introduced to either Thr181, Ser202, Thr212/Ser214 (double alanine mutant), Thr231, Ser262, 
Ser396/Ser404 (double alanine mutant), or Ser404. For this, site-directed mutagenesis was 
conducted using overlap extension PCR (15) using the Phusion DNA polymerase (New England 
Biolabs # M0530) (see Table 4.2 for primers used). Residue numbering of tau is according to the 
longest adult human brain tau isoform. 
Table 4.1 Primers for Golden Gate assembly of plasmids 
DNA template  Primers  
pRK5-EGFP-Tau 5’- TCCGCTGAGCCCCG -3’ 
5’- CCATGGTGGCGACCATC -3’ 
piRFP670-N1 5’- ATGGTAGCAGGTCATGCC -3’ 
5’- CGGATCCGCTCTCAAGCGCGG -3’ 
 
Table 4.2 Primers used for site-directed mutagenesis 
Mutant Primers 
T181A 5’- GAGCTGGGTGGTGCCTTTGGAGCGGGC -3’ 
5’- GCCCGCTCCAAAGGCACCACCCAGCTC -3’ 
S202A* 5’- AGTGCCTGGGGCGCCGGGGCTGC -3’ 
5’- GCAGCCCCGGCGCCCCAGGCACT -3’ 
T212A/S214A 5’- GTTGGAAGGGCCGGGGCGCGGGAGCGG -3’ 
5’- CCGCTCCCGCGCCCCGGCCCTTCCAAC -3’ 
T231A 5’- GACTTGGGTGGAGCACGGACCACTGCCACCTTCT -3’ 
5’- AGAAGGTGGCAGTGGTCCGTGCTCCACCCAAGTC -3’ 
S262A 5’- TTCAGGTTCTCAGTGGCGCCGATCTTGGACTTG -3’ 
5’- CAAGTCCAAGATCGGCGCCACTGAGAACCTGAA -3’ 
S396A/S404A§ 5’- CAGACACCACTGGCGCCTTGTACACGATCTC -3’ 
5’- GAGATCGTGTACAAGGCGCCAGTGGTGTCTG -3’ 
S404A 5’- AGATGCCGTGGAGCCGTGTCCCCAGAC -3’ 
5’- GTCTGGGGACACGGCTCCACGGCATCT -3’ 
 
Note: *Previous study has shown that AT8 recognition requires only Ser202 to be phosphorylated in tau (13). 
          §S396A/S404A were obtained using the S404A mutant as a template to generate double mutations.  
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4.2.2 Cell culture and transfection 
The human embryonic kidney (HEK) 293FT cells a high transfection efficiency isolate of the 
HEK293T cells were purchased from ThermoFisher (# R70007), and used without further 
authentication. The cell line is not listed as a commonly misidentified cell line by the 
International Cell Line Authentication Committee. HEK293FT cells were grown in DMEM 
supplemented with 10 % fetal bovine serum. The cells were frozen at early passage and used for 
less than 2 months in continuous culture. HEK293FT cells were seeded in 24-well plate in the 
same number 2 days before plasmid transfection to reach 70 % confluency. The cells were then 
transfected with plasmid using the Lipofectamine 3000 reagent (Invitrogen # L3000001) 
according to the manufacturer’s instructions.  
4.2.3 Tau antibodies 
10 phospho-tau antibodies raised against 7 phosphoepitopes in tau were validated for their 
specificity (Table 4.3). The following monoclonal antibodies were commercially available: 
AT270 (pThr181), AT8 (pSer202/pThr205), AT100 (pSer212/pSer214), AT180 (pThr231), 
PHF-6 (pThr231), 1H6L6 (pThr231), and anti-tau (pSer404). The following monoclonal 
antibodies were a gift of Dr. Peter Davies: TG-3 (pThr231 and conformation-specific) and PHF-
1 (pSer396/pSer404). One purified rabbit polyclonal antibody anti-tau (pSer262) was purchased 
from Abcam. Tau-5 (Tau210-241, Invitrogen # AHB0042, AB_2536235) is a monoclonal 
antibody recognizing phosphorylated and non-phosphorylated tau isoforms. Purified single-chain 
antibody variable fragment (scFv) 3.24 targeting pThr231 was reported previously (16).  
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Table 4.3 Phospho-tau antibodies 
Name Epitope Host/ 
Isotype 
Source Dilutio
n 
Working 
conc. 
𝚽𝐚𝐥𝐚 𝚽𝛌𝐏𝐏 
AT270 pT181 Mouse/IgG1, k Invitrogen, 
# MN1050, 
RRID: 
AB_223651 
1:100 2 µg/mL 0.80±0.06 0.99±0.01 
AT8 pS202/pT
205 
Mouse/IgG1 Invitrogen, 
# MN1020, 
RRID: 
AB_223647 
1:100 2 µg/mL 0.95±0.07 0.95±0.05 
AT100 pT212/pS
214 
Mouse/IgG1, k Invitrogen, 
# MN1060, 
RRID: 
AB_223652 
1:100 2 µg/mL N/A N/A 
AT180 pT231 Mouse/IgG1, k Invitrogen, 
# MN1040, 
RRID: 
AB_223649 
1:100 2 µg/mL 0.99±0.01 0.98±0.01 
PHF6 pT231 Mouse/IgG1 Invitrogen, 
# 35-5200, 
RRID: 
AB_2533210 
1:250 2 µg/mL 0.98±0.01 0.97±0.00 
1H6L6 pT231 Rabbit/IgG Invitrogen, 
 # 701056, 
RRID: 
AB_2532360 
1:250 2 µg/mL 1.00±0.00 0.99±0.01 
TG-3 pT231 Mouse/IgM Peter Davies 
RRID: 
AB_2716726 
1:100 N/A 0.96±0.01 0.95±0.06 
pS262 pS262 Rabbit/IgG Abcam, 
# ab131354, 
RRID: 
AB_11156689 
1:500 2 µg/mL 0.32±0.02 0.37±0.01 
PHF1 pS396/pS4
04 
Mouse/IgG Peter Davies 
RRID: 
AB_2315150 
1:100 N/A 0.98±0.00 0.98±0.03 
pS404 pS404 Rabbit/IgG Abcam, 
# ab92676, 
RRID: 
AB_10561457 
1:200 0.1 µg/mL 1.00±0.00 0.99±0.00 
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4.2.4 Quantitation of antibody specificity 
Here we define a generally applicable parameter to quantify antibody specificity, based on 
general discussions regarding multi-partner protein interaction by Hall and Daugherty (1). If an 
antibody Ab is capable of binding to n different partners X1, X2, … Xn as described by the 
following reactions, 𝐴𝑏 + 𝑋0 12,4	 𝐴𝑏𝑋0 𝐴𝑏 + 𝑋6 12,7 𝐴𝑏𝑋6 
… 𝐴𝑏 + 𝑋8 12,9 𝐴𝑏𝑋8 
the specificity of the interaction between Ab and Xi can be defined as Φ: where: 
Φ: ≡ 𝐴𝑏𝑋:𝐴𝑏𝑋<8<=0 = 1 − 𝐴𝑏𝑋<¹	:8<=0 𝐴𝑏𝑋<8<=0  
From this definition, 0 < Φ: < 1, where 1 indicates perfect specificity (Ab only reacts with its 
intended antigen Xi), and 0 indicates no interaction with Xi. We used the following formula to 
quantify the specificity of phospho-tau antibodies: 
ΦCDEFCDE = [𝐴𝑏 − 𝑇𝑎𝑢CDEF]𝐴𝑏 − 𝐴𝑔MEMNO  
where 𝑇𝑎𝑢CDEF indicates phosphorylated epitope sequences of tau at a defined site, and 𝐴𝑔MEMNO 
indicates overall potential partners including 𝑇𝑎𝑢CDEF . In our assay, we determined the 
specificity using a three-color labeling scheme, where the mixture of HEK293FT cells 
transiently expressing EGFP tagged WT human tau and iRFP tagged alanine mutant tau was 
incubated with a fluorescence-labeled antibody. In this case, the overall specificity ΦNON can be 
obtained by measuring the following parameter: 
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ΦP = [𝐴𝑏 − 𝐴𝑔NON]𝐴𝑏 − 𝐴𝑔MEMNO  
where 𝐴𝑔NON  indicates antigen with an alanine mutation at the target phosphorylation site. 
Therefore, ΦP in this case indicates the fraction of total binding signal to the alanine mutant 
(non-specific binding signal from cells expressing the alanine mutant). ΦNON is defined as: ΦNON = 1 − ΦP 
Therefore, ΦNON value of 1 indicates no cross-reactivity to the alanine mutant. Experimentally, ΦP was determined by measuring the fluorescence intensity of antibody labeling from each cell 
in flow cytometry experiments (detailed description on how Φ values were obtained is below). 
For example, 
ΦP = 𝐹𝐿0𝐹𝐿6 
where FL1 and FL2 are fluorescence intensity of antibody labeling from HEK293FT cells 
transiently expressing alanine mutant tau and WT tau, respectively. Fluorescence intensity was 
calculated by subtracting the background fluorescence measured on the same day from a control 
antibody with matching isotype. Analogously, ΦSTTis defined by replacing 𝐴𝑔NON with lambda 
protein phosphatase (λPP)-treated antigen (𝐴𝑔STT). ΦSTT value of 1 indicates no cross-reactivity 
to the de-phosphorylated tau. 
4.2.5 Measurement of 𝜱: validation of phospho-tau antibody specificity 
To measure ΦNON  of phospho-tau antibodies, the HEK293FT cells were co-transfected with 
plasmids pRK5-EGFP-tau WT and pcDNA3-GSK3b using the lipofectamine method described 
above. In separate wells, HEK293FT cells were co-transfected with plasmids pRK5-iRFP-tau 
(alanine mutant) and pcDNA3-GSK3b. Cells were detached from 24-well plate using 0.05 % 
trypsin-EDTA (Gibco # 25300-054) for 10 min at 37 oC, then pelleted and washed 1x with ice-
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cold PBSCM (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 1 mM CaCl2, 
and 0.5 mM MgCl2, pH 7.4). The same number of cells from the two transfections were mixed 
and fixed in 4 % paraformaldehyde for 15 min at room temperature in a 1.5 mL microcentrifuge 
tube with gentle rotating. The fixed cells were permeabilized using PBSCM with 0.1 % Triton 
X-100 for 15 min at room temperature, then blocked in PBSG (PBSCM with 40 % goat serum, 
Gibco # 16210-064) for 30 min at room temperature with gentle rotating. For antibody staining, 
these cells were incubated overnight at 4 oC in dark with gentle rotating with tau antibodies 
diluted in PBSG (see Table 4.3 for dilution). The next day, the cells were incubated with either 
Alexa Fluor 594 conjugated secondary anti-mouse IgG antibody (1:500, Invitrogen # A11005, 
RRID: AB_2534073), anti-mouse IgM antibody (1:500, Invitrogen # A21044, RRID: 
AB_2535713), or anti-rabbit IgG antibody (1:500, Invitrogen # A21442, RRID: AB_2535860) 
diluted in PBSG for 1 hour at room temperature in dark with continuous rotating. Pelleting and 
washing 1x with ice-cold PBSCM were required in between each incubation steps. After labeling, 
the cells were re-suspended in ice-cold PBSCM, and the fluorescence signal from cells was 
acquired using Becton-Dickinson Fortessa X20 (UConn Center for Open Research Resources 
and Equipment). The experimenter was not blinded during the experiment. 
To measure ΦSTT, the HEK293FT cells were co-transfected with plasmids pRK5-EGFP-tau WT 
and pcDNA3-GSK3b. In separate wells, cells were transfected with pRK5-iRFP-tau WT plasmid 
only (not co-transfected with pcDNA3-GSK3b), since these cells will be treated with λPP to de-
phosphorylate tau. The same number of cells from the two transfections were fixed and 
permeabilized, separately. After permeabilization, only the cells expressing iRFP-tau WT were 
treated with 2 U/µL λPP (New England Biolabs # P0753) for 3 hours at 30 oC with gentle 
rotating. These cells were then mixed with cells expressing EGFP-tau WT. The following 
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blocking, primary and secondary antibody incubation steps follow the same procedure as when 
measuring ΦNON, described above. The experimenter was not blinded during the experiment. 
4.2.6 Immunocytochemistry in HEK293FT cells 
The HEK293FT cells were seeded in a chamber mounted on #1.0 Borosilicate coverglass (Lab-
Tek # 155383), then co-transfected with plasmids pRK5-EGFP-tau WT and pcDNA3-GSK3b as 
described above. Cells were rinsed 1x with ice-cold PBSCM and fixed in 4 % paraformaldehyde 
for 15 min at room temperature in the chambers. The fixed cells were permeabilized using 
PBSCM with 0.1 % Triton X-100 for 15 min at room temperature, blocked in PBSG for 30 min 
at room temperature, and then incubated with tau antibodies diluted in PBSG overnight at 4 oC in 
dark. The following tau antibodies and dilutions were used: AT270 (1:200), 1H6L6 (1:250), and 
AT180 (1:200). The next day, the cells were incubated with either Alexa Fluor 594 conjugated 
secondary anti-mouse antibody (1:500, Invitrogen # A11005, RRID: AB_2534073) or anti-rabbit 
antibody (1:500, Invitrogen # A21442, RRID: AB_2535860) diluted in PBSG for 1 hour at room 
temperature in dark. 300 nM of DAPI was used to stain the nucleus for 1 min at room 
temperature. 3x washes with ice-cold PBSCM and 5 min incubation on ice in between were 
required during each incubation steps. The cells were imaged using a Nikon A1R confocal 
microscope (UConn Center for Open Research Resources and Equipment). The experimenter 
was not blinded during the experiment. 
4.2.7 Mouse hippocampus dissection 
All procedures involving animals were in accordance with the US National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and approved by the University of 
Connecticut Institutional Animal Care and Use Committee. Hippocampal dissection was 
performed according to the methods we have previously described (2,3). No sample calculation 
  72 
was performed, but was based on previous studies (2,3). Timed pregnant Swiss Webster mice 
(gestational day 15) were purchased from Taconic. P0 or P1 postnatal mice (randomly selected 
from litter using simple randomization (4)) were placed on a physical barrier (such as a glove) on 
top of an ice slurry one at a time to induce hypothermia to reduce or terminate movement and 
bleeding, and decapitated. Hippocampus was dissected from 6 P0 or P1 postnatal mice in Hank’s 
balanced salt solution with 10 mM HEPES, 35 mM glucose, 1 mM kynurenic acid, and 10 mM 
MgCl2, pH 7.4. For dissociation, the hippocampal tissue was digested with 50 units of papain 
(Worthington Biochemical) for 8 min, and halted with ovomucoid trypsin inhibitor (Worthington 
Biochemical). 
4.2.8 HEK293FT and mouse primary cell lysate preparation and western blotting 
The following cell lysates were prepared: non-transfected HEK293FT cells, HEK293FT cells 
expressing EGFP only, HEK293FT cells expressing EGFP-tau WT, and dissociated mouse 
hippocampus. Cells were cultured to approximately 80 % confluency on 100 mm polystyrene 
tissue culture plates and scraped into 1 mL lysis buffer containing 150 mM NaCl, 5 mM EDTA, 
50 mM Tris, 1 % Triton X-100, 0.5 % sodium deoxycholate, and 0.1 % sodium dodecyl sulfate, 
protease inhibitor cocktail (Sigma # P8340), and phosphatase inhibitor cocktails 2&3 (Sigma # 
5726 & P0044). Cells were lysed on ice for 15 min and then centrifuged at 13,000 g for 15 min 
at 4 oC to remove insoluble debris. The concentrations of cell lysate were determined using a 
Bradford assay kit (ThermoFisher Scientific # 23200) according to the manufacturer’s 
instructions. The lysates were aliquoted and stored at -20 oC avoiding multiple freeze/thaw 
cycles. 
An equal amount (15 µg) of total cellular protein was separated by SDS-PAGE using 4-12.5 % 
Bis-Tris gels and transferred to nitrocellulose membrane (GE Healthcare # 10600006). SeeBlue 
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pre-stained protein standard (Invitrogen # LC5925) was used to determine the molecular weight. 
The nitrocellulose membrane was blocked in TBST (20 mM Tris, 150 mM NaCl, and 0.1 % 
Tween 20, pH 7.6) with 1 % BSA (bovine serum albumin, ThermoFisher Scientific #149006) for 
1 hour at room temperature, and then incubated with the tau antibodies diluted in TBST with 1 % 
BSA overnight at 4 oC with continuous agitation. The following antibodies and dilutions were 
used: AT270 (1:1000), 1H6L6 (1:2500), and AT180 (1:1000). The following day, the membrane 
was washed 3x with TBST and then incubated with either horseradish peroxidase-coupled 
secondary anti-mouse antibody (1:2000, Invitrogen # 62-6520, RRID: AB_2533947) or anti-
rabbit antibody (1:5000, Invitrogen # 31460, RRID: AB_228341) for 1 hour at room temperature 
with continuous agitation. The peroxidase activity was revealed using an enhanced 
chemiluminescence detection kit (GE Healthcare, # 16915806). GAPDH antibody (1:2000, 
Invitrogen # MA5-15738-HRP, RRID: AB_2537659) was used as a loading control. The 
experimenter was not blinded during the experiment. 
 
 Results 
4.3.1 𝜱: A generalizable parameter for measuring the specificity of phospho-tau antibodies 
To quantify the specificity of phospho-tau antibodies, we developed a whole-cell based approach 
using flow cytometry (Figure 4.1). To probe the site-specificity of phospho-tau antibodies, we 
generated targeted alanine mutants at defined phosphorylation sites. HEK293FT cells were 
transiently transfected with either WT human tau (0N4R isoform) fused to the EGFP (EGFP-tau 
WT), or a point mutant (an alanine mutant at the phosphorylation site of interest) fused to the 
iRFP (iRFP-tau), in separate wells (Figure 4.1a). Previous reports indicated that endogenous tau 
expression is undetected in HEK293 cells (5,6). In addition, when transfected with human tau, 
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endogenous kinases in HEK293FT cells phosphorylated human tau (7,8). Leveraging these facts, 
we developed a ratiometric assay to quantify the specificity of phospho-tau antibodies (Figure 
4.1a). The EGFP-positive cells (expressing WT tau) and iRFP-positive cells (expressing a tau 
point mutant incapable of phosphorylation at a defined site) were mixed in same numbers and 
incubated with phospho-tau antibodies (Figure 4.1a). The EGFP (green channel) and iRFP (far-
red channel) positive cells, and their antibody binding (red channel) were clearly distinguished 
using flow cytometry (Figure 4.1b, left panel). This assay quantifies the specific binding of the 
antibody to a defined phosphorylation site. In this assay, the phospho-tau antibody AT180, 
targeting phospho-threonine 231 (pThr231) (9-11), showed almost exclusive labeling to the cells 
expressing EGFP-tau WT, and no detectable binding to iRFP-tau T231A (Figure 4.1b), 
indicating that AT180 binding requires pThr231. 
 
Figure 4.1 A ratiometric assay to quantify the specificity of phospho-tau antibodies. 
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a, schematic of phospho-tau antibody specificity quantification assay using HEK293FT. HEK293FT cells were 
transfected with either EGFP-tau WT (12) or iRFP-tau with alanine mutation(s) at the target site (magenta), in 
separate wells. The cells were then mixed and incubated with phospho-tau antibodies. The antibody binding 
was detected using an Alexa Flour 594 conjugated secondary antibody (red). In parallel, HEK293FT cells were 
transfected with either EGFP-tau WT (12) or iRFP-tau WT (magenta), in separate wells. iRFP-tau WT cells 
were treated with lambda phosphatase (λPP) to de-phosphorylate tau, then mixed with EGFP-tau WT cells. 
Scale bars, 50 µm. b, representative flow cytometry results for AT180 showing the alanine mutant experiment 
(left) and de-phosphorylation experiment (right). 
 
In case an antibody shows non-specific binding to the alanine mutant at the target modification 
site, the antibody may be recognizing a phosphorylated residue at an off-target site. In addition, 
the absence of antibody binding to the alanine mutant does not exclude the possibility that 
binding to the non-modified tau is inhibited by the alanine mutation. In other words, the antibody 
may possess non-specific binding to unmodified tau, but may not bind to the alanine point 
mutant. To assess these possibilities, we transfected HEK293FT cells with either EGFP-tau WT 
or iRFP-tau WT separately and treated only the iRFP-tau WT expressing cells with λPP (Figure 
4.1a). As in the assay using the T231A mutant, AT180 showed exclusive binding to EGFP-tau 
WT cells (Figure 4.1b, right panel). This result provides further support that the AT180 antibody 
does not recognize the WT tau epitope without phosphorylation of Thr231.  
We tested the assay (Figure 4.1a) for its ability to discern phospho-specificity using 3 previously 
characterized anti-tau antibodies. Tau-5 is a pan-tau antibody that shows phosphorylation-
independent binding (13,14), 3.24 is a high specificity scFv to pThr231 tau (15), and ab131354 
targets pSer262 tau but have shown cross-reactivity to non-phosphorylated tau (16). Tau-5 
indeed showed binding to both EGFP-tau WT and iRFP-tau WT treated with λPP (Figure 4.2a). 
3.24 showed binding to EGFP-tau WT, but not to iRFP-tau T231A or iRFP-tau WT treated with 
λPP (Figure 4.2b), confirming its high specificity. ab131354 showed cross-reactivity to both 
iRFP-tau S262A and iRFP-tau WT treated with λPP (Figure 4.2c), indicating that it is not 
specific to pSer262 tau. 
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Figure 4.2 Validation of the assay using well characterized anti-tau antibodies 
a, flow cytometry plots for the pan-tau antibody Tau-5, which shows binding to both EGFP-tau WT and iRFP-
tau WT treated with λPP. b-c, flow cytometry plots for the high specificity single-chain variable fragment 3.24 
(b) and ab131354 (c). 
 
Based on this assay, we introduce a parameter termed Φ (see Materials and Methods section for 
definition) that quantifies the specificity of phospho-site targeting antibodies. Φ is determined by 
the degree of cross-reactivity towards cells expressing the target antigen with an alanine point 
mutation at the target phospho-site, or cells expressing the target antigen but were treated with 
λPP for de-phosphorylation. Φ ranges from 0 to 1, where 1 indicates perfect specificity (no 
binding to the alanine mutant or λPP treated cells), and lower Φ indicates more false positive 
detection of nonphospho-tau or phospho-tau at off-target sites. 2 Φ values are derived from the 
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definition: ΦVWV is determined from cross-reactivity to tau with a point alanine mutation at the 
target site, while ΦSTT is determined by cross-reactivity to de-phosphorylated tau. The phospho-
site specificity is determined by evaluating both ΦVWV and ΦSTT values. The specificity ΦVWV and ΦSTT of AT180 were 0.99 ± 0.01 and 0.98 ± 0.01, respectively (Table 4.3, mean ± standard 
deviation from 2 independent experiments, all data points shown in Figure 4.3), indicating 
nearly perfect phospho-site specificity towards pThr231 tau. The specificity ΦVWV and ΦSTT of 
ab131354 were 0.32 ± 0.02 and 0.37 ± 0.01, respectively, reflecting its poor specificity (Figure 
4.2). Φ can be used as a general standard to measure and compare the specificity of post-
translational modification (PTM)-site targeting antibodies. 
 
Figure 4.3 Measurement of 𝚽𝐚𝐥𝐚 and 𝚽𝛌𝐏𝐏 of phospho-tau antibodies. 
Error bars indicate standard deviation from two independent cell culture preparations. Red, ΦSTT. Blue, ΦVWV. 
 
4.3.2 Co-expression of glycogen synthase kinase-3b enhances tau phosphorylation 
The assay developed here relies on intracellular phosphorylation of tau due to endogenous kinase 
activity in HEK293FT cells. Previous studies have found that tau expressed in HEK293 cells 
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were phosphorylated at various sites, including S214, S262, S396/S404 (17). A major advantage 
of our assay is the potential to co-express kinases to induce tau phosphorylation. Since many of 
the residues that are phosphorylated on tau are serine or threonine preceding a proline, we co-
expressed glycogen synthase kinase (GSK)-3b,  a proline-directed kinase, in HEK293FT cells to 
enhance tau phosphorylation. GSK-3b phosphorylates tau at a wide range of sites found in 
Alzheimer’s disease patients (18). Co-transfected cells showed a similar level of EGFP-tau WT 
expression (Figure 4.4a), but enhanced binding to the phospho-tau antibody AT8, which targets 
pSer202 (19-21) (Figure 4.4b), indicating improved phosphorylation. Therefore, to enhance the 
detection of phospho-tau antibody binding, we co-transfected tau constructs with GSK-3b in 
subsequent experiments. 
 
Figure 4.4 Co-expression of GSK-3b in HEK293FT cells enhances phosphorylation of tau. 
a, representative flow cytometry plots for AT8 showing tau expression (EGFP-tau) and AT8 binding cells 
transfected with tau-only (left) or cells co-transfected with tau and GSK-3b (right). b, histograms for tau 
expression (left) and AT8 binding (right) in cells transfected with tau-only (red) or cells co-transfected with tau 
and GSK-3b (blue).  
 
4.3.3 Quantifying the phospho-site specificity of commonly used phospho-tau antibodies 
Using our assay, we quantified the specificity Φ of 7 widely used phospho-tau antibodies 
(AT270, AT8, AT100, AT180, PHF-6, TG-3, and PHF-1) as well as 2 additional phospho-tau 
antibodies (1H6L6 and pS404). Collectively these antibodies have been raised against 6 distinct 
phosphorylation sites (see Table 4.3 for more information) of high relevance in a wide range of 
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neurodegeneration. We applied the same approach described in Figure 4. 1 to quantify both ΦVWV 
and ΦSTT. In Figure 4.5, data in the left two columns show antibody labeling from a mixture of 
cells transfected with either EGFP-tau WT or iRFP-tau with the corresponding alanine point 
mutant. The right two columns show antibody labeling from cells transfected with either EGFP-
tau WT or iRFP-tau WT treated with λPP. Clear binding to EGFP-tau WT was detected in all 
antibodies except AT100 (Figure 4.5, leftmost column). Most antibodies showed exclusive 
binding to EGFP-tau WT, and no binding to the alanine point mutant at their corresponding 
target site or the iRFP-tau WT treated with λPP (Figure 4.5, second and last columns from left). 
From two independent experiments, we obtained highly reproducible measurement of ΦVWV and ΦSTT from these antibodies (Table 4.3 and Figure 4.3). 5 out of 7 antibodies (AT8, AT180, 
PHF-6, TG-3, and PHF-1) had Φ values near 1, indicating these antibodies have nearly perfect 
specificity. For AT270, ΦVWV = 0.80 ± 0.06 (Table 4.3), due to the elevated level of binding 
signal in cells expressing the T181A mutant (Figure 4.5). However, ΦSTT = 0.99 ± 0.01 (Table 
4.3), indicating that the cross-reactivity was not detected in dephosphorylated cells. Taken ΦVWV 
and ΦSTT together, the non-specific signal detected from AT270 was phosphorylation-sensitive 
(see below for further characterization of non-specific binding in AT270). For AT100, the 
absence of binding to EGFP-tau WT cells suggests that the phospho-site (pThr212/pSer214) was 
not phosphorylated in HEK293FT cells, even with co-transfection of GSK-3b. Therefore, we 
were unable to measure the Φ values for AT100. Taken together, these results validate that the 
widely used phospho-tau antibodies AT8, AT180, PHF-6, TG-3, and PHF1 binds specifically to 
tau phosphorylated at the target site, but not to non-phosphorylated tau or phosphorylated tau at 
off-target sites. 
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Figure 4.5 Specificity measurements for commonly used phospho-tau antibodies 
Specificity measurements for commonly used phospho-tau antibodies using the flow cytometry assay 
described in Figure 4.1. Dotted and closed circles indicate observed non-specific binding to cells not 
expressing tau. 
 
4.3.4 Non-specific binding to cells in phospho-tau antibodies 
For the antibody AT270, which showed lower ΦVWV but high ΦSTT, we observed a reproducible 
non-specific binding to cells not expressing tau (dotted circles in Figure 4.5). Similar non-
specific binding was detected with AT100, even though AT100 did not bind to EGFP-tau WT. 
Although not as prominent, a small fraction and weak level of non-specific binding to tau-
negative cells was detected in antibodies 1H6L6 and TG-3 (closed circles in Figure 4.5). For 
other antibodies, background binding to non-transfected cells was not detected. The binding to 
cells not expressing tau indicates that these antibodies exhibit non-specific binding to 
HEK293FT cells. We conducted experiments to rule out the possibility that the non-specific 
binding is originating from the secondary reagents used for detection. Control antibodies having 
matched isotype (mouse IgG1, mouse IgM, or rabbit IgG) followed by the secondary antibodies 
(see Materials and Methods section) were used to label a mixture of cells transfected with either 
EGFP-tau WT, or cells transfected with iRFP-tau WT treated with λPP (Figure 4.6). No non-
specific binding was detected in the secondary reagents, indicating that the non-specific binding 
observed was not due to secondary reagents. 
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Figure 4.6 Flow cytometry plots showing binding of isotype-matching control antibodies under the 
specificity quantification assay conditions 
 
For AT270 and AT100, the population with non-specific binding separated clearly when cells 
were treated with λPP (Figure 4.5, right two columns). Based on this result, we hypothesized 
that the non-specific bindings of AT270 and AT100 are due to cross-reactivity to other 
phosphorylated proteins in HEK293FT cells. In this scenario, cells treated with λPP would show 
decreased level of antibody binding, while untreated cells would have generally elevated 
antibody binding. To test this, we labeled a mixture of cells transfected with either EGFP (not 
EGFP-tau), or cells transfected with iRFP (not iRFP-tau) treated with λPP. In this experiment, 
binding was detected only in GFP-positive cells (Figure 4.7a). Since specific binding to 
phospho-tau in AT100 was not detected, we further analyzed the non-specific binding of AT270. 
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We also analyzed the non-specific binding of 1H6L6, which showed a weak level of non-specific 
binding (closed circles in Figure 4.5). TG-3 was not included in this analysis since the fraction 
of tau-negative cells showing non-specific binding was even smaller. To further assess the non-
specific binding found in AT270 and 1H6L6, we conducted immunocytochemistry experiments. 
Antibodies AT270 and 1H6L6 showed binding in cells not expressing EGFP-tau, while the 
highly specific antibody AT180 showed staining only to EGFP-tau positive cells (Figure 4.7b). 
To assess the broadness of proteins that cause the non-specific binding, we conducted western 
blotting experiments. We probed cell lysates from non-transfected, EGFP-transfected, EGFP-tau 
transfected cells as well as dissociated mouse hippocampus. In these experiments, antibodies 
AT270 and 1H6L6 showed bands in addition to a band corresponding to EGFP-tau (Figure 4.7c). 
In contrast, a single band corresponding to EGFP-tau was observed in AT180 (Figure 4.7c). For 
AT270, off-target bands found in HEK293FT cell lysates were also detected in WT mouse 
hippocampal cell lysate. Therefore, this non-specific binding was independent of species, leading 
to a non-specific band interfering with the mouse tau signal. However, for 1H6L6, the non-
specific binding was not clearly detected in mouse hippocampal lysate, suggesting that the non-
specific binding may be species or cell-type dependent. These results demonstrate that by using a 
whole-cell based approach, we have identified a source of non-specific binding in antibodies 
AT270 and 1H6L6 not observable when using peptides for specificity characterization.  
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Figure 4.7 Non-specific binding to HEK293FT cells in phospho-tau antibodies 
a, flow cytometry plots for AT270 and AT100 to detect non-specific binding to normal HEK293FT cells 
(EGFP-transfected) vs.  λPP-treated cells (iRFP-transfected). b, confocal images of AT180, AT270, and 
1H6L6 antibodies binding to HEK293FT cells transfected with EGFP-tau WT. Images show nuclei stained 
using DAPI (blue), tau expression (12), antibody staining (red), and merge. Scale bars, 25 µm. c, analysis of 
tau signal and non-specific signal in AT270 and 1H6L6 by western blotting. The proteins were extracted from: 
lane 1, non-transfected HEK293FT cells; lane 2, HEK293FT cells transfected with EGFP; lane 3, HEK293FT 
cells co-transfected with EGFP-Tau/GSK-3b; lane 4, mouse hippocampus. Proteins were identified with the 
following antibodies: AT180, AT270 , and 1H6L6.  GAPDH was used as a loading control. 
 
 Discussion 
Site-specific phosphorylation of tau is critical in understanding the molecular biology of tau and 
is a well-defined target in neurodegeneration. The specificity of phospho-tau antibodies is critical 
for reproducible and sensitive detection (15,22). Phospho-tau antibodies should interact only 
with the target epitope sequence with site-specific phosphorylation, and not with nonphospho-tau 
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or phospho-tau at off-target sites. In particular, considering the fact that phospho-tau antibodies 
are being developed for diagnostic tests and clinical trials as therapeutics, a standard measure of 
specificity is urgently needed (23-28) In this study, we developed a whole-cell based assay that 
enables robust measurement of the specificity of phospho-tau antibodies, and introduced the 
specificity parameter termed Φ. Φ is determined by measuring the fraction of binding signal 
from cross-reactivity to nonphospho-tau or off-target phosphorylation sites. Φ ranges from 0 to 1, 
where 1 indicates perfect specificity and lower Φ indicates more false positive detection of either 
nonphospho-tau sequences or the phospho-tau at the off-target site. We measured two Φ values 
(ΦVWV  and ΦSTT ) to comprehensively capture the specificity. ΦVWV  indicates the phospho-site 
specificity of the antibody by measuring the fraction of non-specific binding to an alanine point 
mutant at the target phospho-site. ΦSTT  indicates the phospho-sensitivity of the antibody by 
measuring non-specific binding to de-phosphorylated tau. This approach can be easily adapted to 
other phosphorylated proteins, and potentially to other PTMs such as methylation and acetylation, 
allowing specificity quantification and comparison of any PTM-site specific antibody. In 
addition, the Φ values can be combined to a single parameter, to yield a single specificity 
parameter. For example, ΦXYXVW = 1 − ((1 − ΦVWV) + (1 − ΦSTT)) = ΦVWV + ΦSTT − 1 
In our calculation of the Φ values, we did not include the fluorescence signal detected from cells 
not expressing tau. Therefore, the small non-specific binding to cells we observed for antibody 
1H6L6 (and to an even smaller degree in TG-3) is not reflected in their Φ values. As for AT270, 
the Φ value captured the non-specific binding to cells, since the non-specific binding was 
detected in the cells expressing the alanine mutant but was lost after de-phosphorylation with 
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λPP. We attempted to define another Φ parameter to quantify the non-specific binding to cells 
but the resulting values were inconsistent due to variations in the level of non-specific binding 
signal and fraction of cells showing binding. 
Using our assay, we measured the Φ values of 10 phospho-tau antibodies, 7 of which have been 
used in hundreds of previous studies. Out of the 7, we quantified the specificity of 6 antibodies 
(AT270, AT8, AT180, PHF-6, TG-3, and PHF-1). We were unable to determine Φ values for 
AT100, due to lack of binding to tau expressed in HEK293FT cells. Endogenous kinases in 
HEK293FT cells phosphorylate human tau (7,8). We showed that co-transfection of tau with 
GSK-3b  led to increased phosphorylation of tau, but not for the AT100 target site 
(Thr212/Ser214). Previous studies have indicated that the AT100 epitope is formed only when a 
specific order of phosphorylation occurs (29). It has also been shown that Thr212 and Ser214 are 
sequentially phosphorylated by GSK-3b and protein kinase A (PKA), respectively (29). 
Considering that PKA is commonly expressed in cells, tau expressed in HEK293FT cells may 
only be phosphorylated at Ser214, leading to lack of AT100 binding. Tau phosphorylation may 
be enhanced by using mammalian brain extracts, which contain kinases that phosphorylate tau in 
vitro (29-31). 
Out of the 6 phospho-tau antibodies (AT270, AT8, AT180, PHF-6, TG-3, and PHF-1), all but 
AT270 had Φ values close to 1, indicating near-perfect specificity. For AT270, a weak, but 
reproducible binding was detected to tau-negative HEK293FT cells (Figure 4.5). This non-
specific binding was consistently detected in immunocytochemistry experiments, leading to 
distinct perinuclear non-specific binding (Figure 4.7b). Western blotting with AT270 revealed 
additional bands consistently present in non-transfected HEK293FT cell lysate as well as 
primary WT mouse hippocampal lysate (Figure 4.7c). A previous study found multiple bands 
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when probing WT mouse brain lysate (32). The same study also found non-specific binding in 
antibodies AT8, AT180, and TG-3, using cell lysate prepared from tau knockout mice. However, 
this non-specific binding was not due to the antibodies themselves, and was eliminated by 
switching secondary reagents (32). We found that the two Φ values for AT270 was inconsistent 
(ΦVWV = 0.80 ± 0.06 vs. ΦSTT = 0.99 ± 0.01). This indicated that the source of cross-reactivity 
was lost upon de-phosphorylation with λPP, suggesting that AT270 may bind to another 
phosphorylated protein. Indeed, the non-specific binding was only detected from the tau-negative 
cells expressing EGFP, but not from the tau-negative cells expressing iRFP with de-
phosphorylation treatment (Figure 4.7a). 
A major advantage of our specificity assay is the use of flow cytometry, which allows sensitive, 
quantitative detection of antibody binding. We enabled the distinction of non-specific binding 
within a single sample by tagging potential cross-reactive proteins with a fluorescent protein 
easily distinguishable from the WT target protein. These features led to the reproducible 
measurement of Φ values for a wide range of phospho-tau antibodies. Previously, peptide arrays 
have been used to validate the specificity of PTM-specific antibodies, such as those targeting 
histone modifications (33-35). Synthetic peptides and peptide arrays were also used for 
specificity analysis of phospho-tau antibodies (16). The limitation of this approach is the high 
cost of synthesizing peptides in order to comprehensively cover tau phosphorylation sites. 
Moreover, short peptides do not have strong binding to conformation-sensitive phospho-tau 
antibodies, such as TG-3 (10). Our approach allows assessment of binding to full-length tau with 
defined sequence variations, and can be co-expressed with kinases to induce tau phosphorylation. 
Using our approach, the specificity of the conformation-sensitive pT231 tau antibody TG-3 was 
also successfully determined (Figure 4.5 and Table 4.3). Libraries of tau mutations may be 
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generated, and deep sequencing approaches can be used for de novo identification of anti-tau 
antibodies. Our approach also revealed non-specific binding of antibodies to irrelevant cellular 
proteins. We found that the source of non-specific binding for AT270 is conserved across 
HEK293FT cells and mouse primary hippocampal cells, but was not conserved for 1H6L6, 
indicating cell-type and species sensitivity of non-specific binding. Further analyses using 
immunoprecipitation and mass spectrometry may allow the identification of the cross-reactive 
proteins.  
Since the cross-reactivity of antibodies would be dependent on the affinity to the off-target sites 
or molecules, it is possible that the Φ values are dependent on antibody concentration. In 
particular, the Φ values may decrease upon increasing antibody concentration. In our 
experiments, we used antibody concentrations typically used for cell labeling experiments (2 
µg/mL, Table 4.3). Since we observed high antibody binding signal in these experiments for all 
antibodies tested except AT100 (which showed non-specific binding to cells), we did not attempt 
to increase the antibody concentration. Also, all antibodies that showed binding had near-perfect 
specificity, except AT270 and ab131354. Lowering the antibody concentration for these 
antibodies resulted in a significant decrease in antibody binding, and did not result in 
improvement of Φ values (data not shown). Even for the high specificity antibodies, users should 
be cautious when using them at higher concentrations than what is listed in Table 4.3, since that 
may result in increased non-specific binding. 
 
 Conclusion 
In summary, our study provided a whole-cell based approach to validate the specificity of 
phospho-tau antibodies. Using this assay, we determined the parameter Φ for phospho-tau 
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antibodies, that enable quantitative comparison of specificity. We anticipate that this parameter 
will be widely adopted in guiding users of the specificity of phospho-tau antibodies, and 
potentially PTM-specific antibodies in general. 
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 Conclusion 
This work has addressed the problems of generating and characterizing high-specific and high-
affinity phospho-tau antibodies. We introduced a yeast display approach to quantify the 
specificity of PTM-specific antibodies, and developed a screening assay based on it to generate 
PTM-specific antibodies with improved affinity and high specificity. We demonstrated that 
improving PTM-specific antibody affinity through directed evolution results in cross-reactivity 
to the non-modified target sequence, there’s a trade-off between affinity and specificity in PTM-
specific antibodies. The results from this study demonstrate that in vitro affinity maturation is a 
viable option for improving the affinity of PTM-specific antibodies. In this process, it is essential 
to quantify the specificity, particularly to the non-modified target sequence. By quantifying the 
specificity, it is possible to apply selection pressures for improved affinity and specificity 
simultaneously. 
We also developed a whole-cell based approach to quantify the specificity of phospho-tau 
antibodies and introduced a parameter Φ to measure their specificity. We anticipate that this 
parameter will be widely adopted in guiding the use of phospho-tau antibodies, and PTM-
specific antibodies in general. 
 
 Future perspectives 
5.2.1 Avidity effect on antibody screening assay 
Antibody affinity and avidity 
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Antibody affinity measures the interaction strength between an epitope and the antigen binding 
site on antibody. It is defined by a measure of dynamic equilibrium of the reversible 
biomolecular interaction. 
Calculation of binding affinity for antibody-antigen interaction (1 antibody binding site per 1 
antigen): 𝐴𝑏 + 𝐴𝑔 ⟺ [𝐴𝑏 − 𝐴𝑔] 
where [Ab] is the unbound antibody concentration, [Ag] is the unbound antigen concentration, 
and [Ab-Ag] is the concentration of the antibody-antigen complex. 
Calculation of dissociation constant, which is the affinity constant (Kd): 
𝐾𝑑 = 𝑘E``𝑘E8 = 	 𝐴𝑏 [𝐴𝑔][𝐴𝑏 − 𝐴𝑔] 
where 𝑘E8 is a constant used to characterize how quickly the antibody binds to its target, and 𝑘E`` is a constant used to characterize how quickly an antibody dissociates from its target. 
High affinity antibodies bind quickly to the antigen, allowing sensitive binding and detection in 
assays under difficult conditions. Low affinity antibodies bind slowly and weakly to the antigen 
and often fail to detect the antigen in assays. 
Antibody avidity refers to the accumulated strength of multiple antigen-binding sites interact 
with the target epitopes simultaneously. Avidity is thought as the combined effect of all affinities 
involved in the biomolecular interaction, which is referred to as functional affinity (1). Nature 
uses multivalency to govern many biological processes.  
Avidity effect on antibody screening assay 
All antibodies are at least bivalent or multivalent, however, the engineered binding proteins 
developed from in vitro screening assay are generally monovalent. When generating novel scFvs 
or nanobodies using in vitro screening assay, it is extremely difficult to discover binders in the 
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initial rounds of screening due to their low affinity. The greater valency of an antibody, the 
greater the amount of antigen it can bind. Similarly, antigens can demonstrate multivalency 
because they can bind to more than one antibody. Multimeric interactions between an antibody 
and an antigen slow their dissociation and stabilize the binding. Individually, each binding 
interaction may dissociate quickly, however, when many binding interactions are present at the 
same time, transient unbinding of a single site does not allow the molecule to dissociate away, 
and binding of that weak interaction is likely to be restored. Therefore, we hypothesize that 
avidity effect on yeast displayed scFvs can increase the possibility to obtain rare low affinity 
binders, and we can develop a new screening assay based on it. 
In order to test our hypothesis, we will assess the impact of avidity of yeast displayed pT231 
scFv on its binding to the target phosphopeptide. Three parameters are involved in this study, 
and the relevant specific aims are: 
i. Affinity of the scFv for the phosphopeptide 
In Chapter 3, we have identified some scFv mutants those only bind to target phosphopeptide 
but have no cross-reactivity to nonphospho-peptide or scrambled phosphopeptide. We will assess 
the affinity of yeast displayed mutants for the target phosphopeptide and select the high-affinity 
mutants, moderate-affinity mutants, and low-affinity mutants. We will measure the dissociation 
rate of these mutants. 
ii. Valency of the phosphopeptide 
The valency of the phosphopeptide can be increased by streptavidin-biotin interaction. 
Streptavidin has the ability to bind up to four biotin molecules (Figure 5.1) with an extremely 
high affinity (Kd=10-14 M) (2). The bond between streptavidin and biotin is one of the strongest 
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non-covalent interaction. It is unaffected by pH, temperature, organic solvents and other 
denaturing reagents once formed.  
 
Figure 5.1 Schematic of the Streptavidin-biotin interaction 
Streptavidin can bind up to four biotin or biotinylated molecules, which is conjugated to a target 
phosphopeptide to form a streptavidin-biotin complex. 
 
The valency of phosphopeptide can be controlled by incubating the streptavidin with different 
ratios of biotinylated phosphopeptide and free biotin. We will label the yeast displayed scFv 
mutants with those pre-incubated phosphopeptide complex, and measure the dissociation rate of 
each mutants in different conditions. 
iii. Structural arrangement of the functional scFv  
More functional scFvs expression per yeast cell also contributes to the avidity effect. A favorable 
structural arrangement of functional scFvs increases the local concentration of phosphopeptide 
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binding sites. Once the first phosphopeptide binds to an scFv on the yeast surface, the chance of 
a bivalent, trivalent, and/or tetravalent interaction are improved. 
To enable this idea, we will assess the impact of linker length between yeast wall protein Aga2p 
and scFv on avidity effect (Figure 5.2). We will insert a longer polypeptide linker between 
Aga2p and the pT231 scFv, allowing more functional scFvs cluster together. We will measure 
the dissociation rate of the same scFv in different yeast surface display formats. 
 
Figure 5.2 Schematic of yeast surface display formats 
The yeast surface display vector encodes scFv as a fusion to the C-terminus of Aga2p with a shorter 
polypeptide linker (left), and a longer polypeptide linker (right). 
 
5.2.2 Application of binding proteins in optogenetics 
The discovery of light-gated ion channels and their application to control neural activities have 
had a transformative impact on the field of neuroscience. In recent years, the concept of using 
light-activated proteins to control biological processes has greatly diversified into other fields, 
driven by the natural diversity of photoreceptors and decades of knowledge obtained through 
their biophysical characterization. This strategy, commonly referred to as optogenetics, is 
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particularly powerful in deciphering the role of targeted neural cells within their complex native 
environment. 
The development intracellular binding proteins for neural proteins, such as tau, combined with 
optogenetics tools allows the visualization of complex structures such as the synapse that are 
critical for understanding neural function. These technologies have the potential to pinpoint the 
location of proteins in fine neuronal structures and reveal the changes occurring in these 
structures under diseased state. Therefore, our screening assay on improved affinity and high 
specific antibody will be applied to develop intracellular binding proteins for key neural target 
proteins and coupling optogenetics to these binding proteins for studying target protein function 
in the future. 
Introduction 
The word ‘optogenetics’ was initially used within the context of neuroscience (3), to describe the 
approach of using light to image and control neuronal activity in the intact, living brain. The idea 
of controlling biological function using light has been around for a long time, but it is in the field 
of neuroscience that its need as a truly enabling tool has been envisioned early on (4,5), and 
remarkably to the realization of such potential (6-8) with wide acceptance over the past decade. 
The success of optogenetics in neuroscience has sparked interest of many scientists and 
engineers in other fields, and now the definition of optogenetics has broadened to encompass the 
general field of biotechnology that combines genetic engineering and optics to enable gain or 
loss of well-defined function, often in the intact animal (9,10). 
Original concepts: a brief historical perspective 
The seed for the birth of optogenetics in neuroscience may have been planted for a long time by 
the pioneering work of Ramón y Cajal, who provided foundational evidence that neurons are the 
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signaling units of the nervous system, and that they exist in many distinctive morphologies (11). 
Since then, studies followed to show that indeed many different types of neurons exist, classified 
based on their physiological characteristics, anatomical location, morphology, and gene 
expression profile (12-14). It is still unclear how many cell types exist in the human brain, but it 
is speculated that there are about 1,000 neuronal cell types just within the mammalian cortex 
(15,16). In a general sense, it is agreed that a specific cell type carries out the same function 
within a neural circuit (17). Therefore, identification of all cell types and mapping out their 
connectivity is essential in order to understand how the nervous system works.  Identification of 
different cell types must be accompanied with functional characterization within their normal 
context, the nervous system.  For this reason, neuroscientists have been looking for a way to 
perturb individual cell types within the intact brain.  This was clearly expressed by Francis Crick 
in his insightful discussion published in 1979, in which he proposed the need for a ‘method by 
which all neurons of just one type could be inactivated, leaving the others more or less unaltered’ 
(4). 
Optogenetics is arguably the first technological breakthrough that enables such experiments.  It 
makes the crucial connection between cell-type information and the ability to perform gain or 
loss of function experiments.  Prior to the development of optogenetics, experimental approaches 
existed in neuroscience to use light as a way to control neural activity.  For example, ‘caged’ 
compounds such as secondary messenger molecules, ions, and neurotransmitters have been 
developed that are initially inert, but become active upon light illumination (18,19).  Even 
though these photochemical approaches did not provide ways to control specific cell-types, they 
laid the groundwork for the use of millisecond timescale illumination in intact cells and tissue 
(19).  Cell-type specific activation of neurons was first achieved in a series of pioneering work 
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by the Miesenböck group, by heterologously expressing an invertebrate rhodopsin with other 
interacting proteins (20), and ligand-gated ion channels that can be activated by synthetic photo-
caged precursors (21,22).  Around this time, microbial rhodopsins that function as single 
component light-gated ion channels were discovered (23-25).  Remarkably, these microbial 
photoreceptors could be heterologously expressed in mammalian neurons to optically trigger 
action potentials with millisecond timescale precision (6).  These findings, along with the fact 
that these rhodopsins contain a covalently bound all-trans retinal chromophore naturally 
produced in nearly all cell types including mammalian cells and tissues (26,27), catalyzed the 
wide adoption of these molecules in neuroscience. 
Genetic targeting: cell-type specificity and beyond 
As discussed above, cell-type specificity is a defining feature of optogenetic experiments.  In 
some ways, gain or loss of function experiments on distinct cell types is analogous to genetic 
knock-in or knockout experiments in molecular biology.  However, while the definition of gene 
is clear, the definition of cell type can be ambiguous and variable. This is particularly true in 
highly complex systems such as the mammalian neocortex (17,28). To account for such high 
complexity, many parameters have been used to describe each cell type, such as developmental 
lineage, anatomical location, dendritic and axonal morphology, electrophysiology, and gene 
expression. Nonetheless, recent advances in single cell analysis methods have provided evidence 
that gene expression patterns can capture many of these diverse cellular phenotypes (12,29). 
Therefore, the use of genetically encoded tools is well justified for probing the function of each 
cell type, and is likely to expand as we gather more gene expression data.   
In principle, optogenetic tools can be driven by cell-type specific promoters or enhancers (30,31) 
to achieve cell-type specific expression. However, this approach is not suitable in many cases for 
  101 
several reasons.  First, it is rare to find a single genetic regulatory element exclusive for a given 
cell type.  Cell identity in most cases seems to be defined by a combination of multiple gene 
expression patterns (10,12,17,32).  Even when cell-type specific genetic regulatory elements are 
accessible, they may not drive high enough expression of optogenetic tools for efficient control 
(33). Moreover, reproducing endogenous expression pattern of genes requires the entire 
transcription unit and all associated regulatory factors (13), which are unknown in many cases, 
and can be hard to transport. A widely used strategy to achieve cell-type specific expression that 
circumvents these problems is using viral vectors in transgenic animals expressing recombinase 
in genetically defined population of cells. In this approach, viral vectors such as lentivirus or 
adeno-associated virus (AAV) carry an optogenetic tool under relatively strong promoters such 
as EF-1a promoter (Figure 1). The optogenetic tool encoding gene is initially present in reverse 
frame to prevent expression, and requires recombinase activity for inversion and subsequent 
expression (Figure 1). The recombinase gene expression is driven in genetically defined cell 
types, for which the expression level is relatively unimportant. Cre-recombinase has been widely 
used for this purpose, due to the availability of increasing number of cell type specific Cre-
transgenic lines (34). Recently, this approach has been further developed to enable targeting of 
neural cell types defined by multiple genetic markers. Transgenic animals that express multiple 
recombinases driven by independent promoters are infected with viral vectors carrying a 
combination of these recombinase sites, resulting in intersectional targeting (35,36). 
Using viral vectors also enable other useful modes of targeting. One approach is to target 
neurons based on their axonal projections or synaptic connectivity (Figure 1). For example, 
modified rabies virus can retrogradely transduce neurons (37,38), while herpes simplex virus and 
vesicular stomatitis virus can anterogradely transduce across axon terminals (39,40). These 
  102 
viruses can be used to deliver Cre-recombinase transsynaptically (39,41), allowing the targeting 
of neurons projecting to genetically defined populations. Recently, it was also shown that certain 
serotypes of AAV also can mediate efficient retrograde transduction (42). These tools enable 
targeting optogenetic tools based on their axonal projection (43-45) and potentially synaptic 
connectivity. 
Another targeting strategy is to express genes using promoters and enhancers induced by 
neuronal activity. These genetic elements were identified from immediate early genes that are 
known to rapidly induce expression upon neuronal activity (46,47). In many cases, these 
elements are triggered by calcium influx that activates calcium-dependent kinases (48). These 
promoters have been used to specifically express optogenetic tools in neurons that gain activity 
during specific behavioral tasks in rodents, such as fear conditioning (49). In a set of impressive 
demonstrations, Liu and others showed that these neurons could be specifically re-activated 
using the light-gated ion channel channelrhodopsin-2 (ChR2) driven by the activity-dependent 
promoter of c-Fos (49,50). This re-activation recreated the original behavior with only light-
activation, indicating optically controlled memory recall (49). Ramirez and others later used the 
same approach to trigger fear response by optically activating a set of neurons activated during 
fear conditioning, demonstrating the creation of false memory (51). Conceptually, these 
demonstrations show that optogenetics can be used to reactivate cell populations specifically 
activated during a behavioral task, enabling activity-based targeting. Considering the diverse 
functionality of transcription factors that can sense a wide range of input signals (52-54), such 
responsive transcription may be a generalizable approach to express optogenetic tools to control 
cell populations that drive a specific functional output. 
Customizing photoreceptors for designed control: modes of action 
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The use of microbial rhodopsins in mammalian neural cells is an inspiring demonstration of 
customizing naturally existing photoreceptors for controlling physiological properties in a 
completely new context. Owing to the diverse modes of action found in photoreceptors (Figure 
2), the concept of re-purposing naturally existing parts to control new biological functions has 
been implemented in many applications, and is expected to further develop as new 
photoreceptors continue to be discovered.  
Microbial rhodopsins (type 1 rhodopsins) mediate either transmembrane ion transport (Figure 2a, 
b) or light sensing through signal transduction (Figure 2c). Microbial rhodopsins that mediate 
light-driven ion transport have been widely used to control membrane potential in mammalian 
neurons (7). They can be categorized into two mechanistically distinct forms: ion pumps (Figure 
2a) that can transport ions against their gradient and channels (Figure 2b) that passively conduct 
ions along the gradient established by other active transporters. Interestingly, all known light-
driven ion pumps result in hyperpolarization of membrane potential through outward transport of 
proton or inward transport of chloride ion (55). When heterologously expressed in mammalian 
neurons, they generate enough current to enable optical silencing (7,56-58). Recently, a light-
driven chloride pump with high sensitivity for far-red light named Jaws has been described that 
enabled non-invasive neural silencing through the intact mouse skull (59). A light-driven 
outward sodium pump (KR2) has also been found recently (60), that may be used for optical 
silencing of neurons. Unlike ion pumps, microbial rhodopsin ion channels cannot transport ions 
against their gradient, but enable control of membrane potential through selective conduction of 
specific ions. First described examples are channelrhodopsins found in the green alga 
Chlamydomonas reinhardtii (23,24), which conduct cations including proton, sodium, potassium, 
and calcium ions (24). Even though the conductance of these channels are relatively low (about 
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100-fold lower than high-conductance ion channels) (61,62), their current depolarize mammalian 
neurons above their threshold to initiate action potentials (6). Recently, more than 60 
channelrhodopsin homologues were identified by conducting a systematic search of 
transcriptome from 127 species of alga (63). This study resulted in a high sensitivity 
channelrhodopsin with extremely fast channel kinetics named Chronos, and a red-sensitive 
channelrhodopsin named Chrimson that as a pair enabled independent multi-color activation of 
two distinct neural populations (63). Another recent study identified anion-conducting light-
gated channels in the cryptophyte Guillardia theta that enabled rapid and reversible optical 
silencing of rat neurons (64). So far, microbial sensory rhodopsins have not been applied in 
optogenetic experiments, perhaps due to the requirement of transmembrane or soluble 
transducers that are not readily compatible with other cell types. In depth discussion of 
biophysical properties of microbial rhodopsins and their impact as optogenetic tools have been 
discussed elsewhere (65).  
Animal rhodopsins (type II rhodopsins) share structural homology to microbial rhodopsins, but 
act as G-protein coupled receptors (GPCRs) that upon light illumination, catalyze GDP to GTP 
exchange in heterotrimeric G proteins. In fact, rhodopsins constitute the largest GPCR family – 
over 700 rhodopsin-like GPCRs have been found in humans (66). Based on the extensive 
structure-function relationship studies of GPCRs (67,68), Khorana and colleagues demonstrated 
that the cytoplasmic domains of a bovine rhodopsin can be replaced by analogous sequences 
from a non-light sensitive GPCR, such as β2-adrenergic receptor (β2-AR) to create a chimeric 
light-sensitive β2-AR (69). This strategy has been extended to create light-driven rhodopsins 
coupled to Gq and Gs signaling pathways (70), Gi/o coupled pathways (71,72). It was also found 
that heterologous expression of unmodified forms of rhodopsins into non-expressing cells can 
  105 
mediate light-driven activation of endogenous G-proteins of the host cell (73). Unlike microbial 
rhodopsins that keep the retinal chromophore throughout the photocycle, certain animal 
rhodopsins such as bovine rhodopsin lose the chromophore after light-activation, requiring 
consistent supply of retinal cofactors (74). Fortunately, in mammalian cells and in brain tissue, 
sufficient concentration of retinal cofactors are present to generate enough functional rhodopsins. 
However, even in cell types where the retinal chromophore is less abundant, the retinal cofactor 
supplementation may be avoided by using ‘non-bleaching’ G-protein coupled opsins that remain 
associated with the chromophore (75). 
Other than rhodopsins based photoreceptors, light-sensing proteins found in plants and microbes 
have been applied in controlling cell signaling in diverse cell types, including mammalian cells, 
yeast, and bacteria. These proteins function by inducing light-triggered conformational change 
coupled to other protein domains (Figure 2e), homo/hetero dimerization (Figure 2f), or 
multimerization (Figure 2g). A prominent example that undergoes conformational change upon 
light-activation is the Light-Oxygen-Voltage (LOV) domains found in photoreceptor systems of 
plants, fungi, and bacteria (76,77). In these systems, LOV domains may control the activity of an 
effector domain directly fused to it through allosteric coupling or steric inhibition. For example, 
the bacterial chemosensor FixL was made light-activatable by replacing its Per-ARNT-Sims (78) 
motif (which is structurally homologous to LOV domains) with the LOV domain Ytva (79). In 
this example, an a-helical coiled coil linker of the LOV domain undergoes a rotational 
movement upon light activation, which activates a histidine kinase domain fused to it. In other 
examples, the conformational change in the LOV domain leads to unfolding of an a-helix in the 
lit-state, resulting in ‘uncaging’ of the effector domain fused to it (Figure 2e). Such light-
activated uncaging approach has been successfully applied in several synthetic constructs 
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including a photo-activatable GTPase Rac1 and Cdc42 (80), peptide binding motifs (81), and 
tethered toxins (82). Even though such photo-uncaging approach seems to be a generally 
applicable design, in many cases it requires several levels of optimization customized to each 
molecule for effective control. For instance, in the photo-activatable Rac1, Ca2+-mediated 
interaction between residues at the interface of the LOV domain and Rac1 turned out to be 
crucial for effective light control (83). Since such conformation-dependent interactions are hard 
to be predicted, de novo design of a photo-activatable construct still remains a challenge. Such 
difficulties may be overcome by using Dronpa, which is a photo-activated fluorescent protein 
that seems to allow modular design of optical control. Upon light-activation, Dronpa not only 
changes fluorescence, but also monomerizes through the unfolding of a β-sheet (84). This feature 
has been used to design photo-activatable GTPases and proteases (85). 
Another mode of action found in photoreceptor domains is light-induced interaction. Certain 
LOV domains, such as the fungal LOV domain Vivid (VVD) (86) and bacterial LOV domain 
EL222 (87) homo-dimerize upon light activation (Figure 2f). Other photoreceptor domains such 
as Arabidopsis thaliana Cryptochrome-2 (CRY2) and Phytochrome B (PhyB) hetero-dimerize 
with a specific partner (Figure 2f), cryptochrome-interacting basic helix-loop-helix 1 (CIB1) and 
phytochrome interacting factor (PIF), respectively (76). Such light-induced interactions have 
been used primarily to control intracellular signaling, by recruiting signaling proteins to or away 
from a specific intracellular site of action, resulting in signal activation or inhibition through 
sequestration. Activities of various kinases, including Ras/ERK (88), phosphoinositide-3 kinase 
(PI3K) (89), and receptor tyrosine kinase (90) (91) have been controlled using this approach. 
Several studies also demonstrated optical control of DNA transcription using light-induced 
binders that mediate the recruitment of transcription activation domains (92,93) or activation of 
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Cre-recombinase (94,95). Interestingly, CRY2 has been shown to undergo multimerization upon 
illumination (Figure 2g), which has been used to mediate light-dependent activation of Rho 
GTPase (96), RTK fibroblast growth factor receptor (97), and actin polymerization (98). The use 
of photoreceptors for optogenetic control of cellular signaling pathways has been extensively 
reviewed recently (65,99,100). 
Engineering photoreceptors: a multi-dimensional problem 
Even though it seems that natural photoreceptor systems rely on modularity of light-activated 
protein domains for controlling diverse signaling pathways (76,101), development of a new 
optogenetic tool in general requires significant engineering efforts for effective control. One 
major challenge is achieving adequate expression of optogenetic tools. As seen in the case of 
microbial opsins, the expression level of an optogenetic construct may be one of the limiting 
factor in achieving effective control. Heterologous expression of photoreceptor domains depends 
on the host cell type, and may yield low levels of functionally active form of the optogenetic tool. 
For example, a study that systematically compared channelrhodopsin homologues found that less 
than half of them show detectable ion conduction when expressed in a mammalian cell line, and 
even less are functionally active in neurons (63). One strategy to improve functional expression 
is to enhance the protein trafficking to the desired compartment using targeting sequences 
(58,102). However, this approach is not generalizable (103), and achieving adequate expression 
of optogenetic tools in the desired cell type remains a challenge. 
Another major challenge is the fact that optogenetic tools require multiple properties to be 
optimized. For example, critical properties of channelrhodopsins that impact their effectiveness 
in controlling neural activity include ion conductance, light sensitivity, spectral sensitivity, 
channel kinetics, and ion selectivity. Structure-guided mutagenesis studies have resulted in 
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improved channelrhodopsins with fast kinetics (104), enhanced photocurrent (105,106), red-
shifted spectral sensitivity (107), and altered ion selectivity (108,109). These studies 
demonstrated that key properties can be tuned using mutagenesis, but also revealed that a single 
mutation often affects multiple properties (Figure 3). For example, mutations at E123 in ChR2 
(corresponding to D85, which is the Schiff base counter-ion in bacteriorhodopsin), affect channel 
kinetics and red-shifts the action spectra (104).  Mutation H134R in ChR2 enhances photocurrent 
perhaps due to improved membrane expression, but slows channel kinetics (62,110). Mutations 
C128 and D156 slow down the channel kinetics drastically, which help to keep open channels for 
longer periods of time, effectively enhancing the light sensitivity (111,112). The trend of 
multiple property modulation by a single mutation is also found in LOV domains. For example, 
in the Avena sativa phototropin 1 LOV2, mutations in the highly conserved residue Q513 reduce 
the structural changes between the dark and the lit state and slow down the dark state return rate 
(113). In addition, in the LOV domain VVD, mutations in M135 and M165 slow recovery 
kinetics and enhance the affinity of the lit-state VVD dimer (114). Therefore, optimization of an 
optogenetic tool requires multi-dimensional characterizations to measure all essential parameters 
(112), and in certain cases individual properties may not be independently optimized. In other 
words, the fitness landscape of photoreceptors is a multi-dimensional space composed of 
potentially dependent parameters. Since typical screens used for protein engineering rely on 
rapid measurement of one or two parameters, strategies such as directed evolution to optimize 
one parameter may result in de-optimization of others that are critical for tool performance. 
Currently, the general strategy is to combine random mutagenesis based methods with structure-
guided approaches and rely on additive beneficial effects of multiple mutations to yield an 
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optimal construct (108,109,115,116). In the future, screens that can characterize multiple 
parameters may be developed to perform multi-dimensional optimizations. 
Analogies to optical imaging: multi-color imaging vs. optogenetics 
Another major direction in optogenetics has been to use multiple colors of light to control two 
independent cell types or processes using photoreceptor domains that have distinctive spectral 
sensitivities. This approach has been extensively explored using microbial opsins. For instance, 
ChR2, which has maximal sensitivity for blue light has been combined with a halorhodopsin 
which can be activated with yellow light to enable bi-directional control of neural activity 
(56,57). Proton pumps with separation in their spectral sensitivity have been used to achieve two-
color neural silencing (58). Even though these studies demonstrated that triggering or inhibiting 
action potentials in neurons can be controlled by leveraging the difference in spectral sensitivity 
of microbial rhodopsins, a recent study showed that achieving multi-color control relying on 
spectral separation alone may result in cross-talk, due to the inherent blue-light sensitivity found 
in rhodopsins (63,82). Even the red-sensitive channelrhodopsin Chrimson was shown to trigger 
action potentials under strong blue light in neurons with high expression levels (63). However, 
detailed biophysical characterization of Chrimson revealed that its channel opening rate under 
blue light is substantially slower than that under red light, and is also dependent on light intensity 
(63). Therefore, cross-activation of neurons under blue light was minimized by pairing Chrimson 
with the fast and light-sensitive channelrhodopsin Chronos and limiting the intensity and 
duration of blue light (63). The blue-light sensitivity of microbial rhodopsins may not be 
completely abolished unless the choromophore itself is altered. Many photoreceptors, including 
LOV domains and cryptochromes are also maximally sensitive to blue light. Therefore, strategies 
other than relying on spectral separation alone, such as leveraging differences in light sensitivity 
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and kinetics under blue light may be necessary to reduce cross-talk for multi-color control using 
other photoreceptors. 
Although the concept of multi-color control in optogenetics may seem analogous to multi-color 
fluorescence imaging, there are several practical differences that require caution in designing 
optogenetic experiments with multiple light sources. In multi-color fluorescence imaging, cross-
activation of fluorophores occurs quite often, but the emission from multiple fluorophores can be 
filtered to obtain cross-talk free images. In experiments using light-activated proteins, any cross-
activation causes change that cannot be filtered or eliminated. Depending on the biological 
question asked, small changes induced by cross-activation may become important, such as in 
experiments that focus on sub-threshold changes in membrane potential. Therefore, when 
designing experiments that require multiple sources of light, such as using light-gated ion 
channels with calcium reporters (117), the wavelength of light used for imaging should be 
chosen cautiously to prevent activation of optical actuators. It is notable that blue-sensitive 
channelrhodopsins that seem to have negligible red-sensitivity can cause membrane 
depolarization under intense red light (116). As described above, strategies that capitalize on all 
aspects of biophysical properties of photoreceptors may be used to prevent cross-activation, but 
may be difficult to completely eliminate small changes induced. 
Conclusion and future perspectives 
Over the past decade, optogenetics has made a major impact on neuroscience research, by 
enabling the control of specific cell types in the intact brain. A powerful integration of optical 
control methods with various detection methods enables closed-loop control of biological 
systems, as achieved by several studies that demonstrated closed-loop control of neural circuit 
(118-120) and feedback-regulated control of cell signaling (121) and gene expression levels 
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(122). These studies indicate that optogenetic approaches will enable us to reveal the underlying 
mechanisms behind complex intracellular signaling systems or multi-cellular dynamics and 
precisely tune it to achieve a desired outcome. They will also allow us to develop and test models 
of intact, complex biological systems. 
Successful development of new optogenetic tools and their implementation is an 
interdisciplinary effort that requires tools tailored to the specific biological process studied. 
Targeting and achieving optimal expression in the desired cell type need to be tested, and the 
biophysical properties of photoreceptors used need to be optimized to the spatial and temporal 
properties to be controlled. Therefore, users of optogenetic tools need to understand their 
biophysical characteristics, and tool developers need to identify key properties and find ways to 
tune them. 
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